UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
FDA decisions, PDUFA dates, advisory committees and clinical-trial readouts for publicly traded biotech stocks.
Tables updated: October 4, 2026; glossary reviewed: September 19, 2026This is Merlintrader’s dedicated biotech catalyst calendar. It tracks upcoming FDA decisions, PDUFA target dates, advisory committee meetings, NDA and BLA milestones, regulatory submissions and major clinical-trial readouts for publicly traded biotech and healthcare companies, including selected non-U.S. listings with FDA milestones.
Each entry is designed to show the expected timing, event type, company context and available source trail. The tables separate confirmed dates, conference ranges, estimated company windows and recent history. Each entry links to its sources; the embedded calendar provides a wider archive.
Catalyst dates can change, FDA decisions can arrive early or late and clinical readouts can be postponed. Always confirm each event against company filings, official press releases and regulatory sources before making any trading or investment decision.
These tables are an editorial selection of events supported by primary sources. Regulatory dates, confirmed presentations and company windows are separated; passed or completed events appear only in history, with their verified status stated. A PDUFA date is a review goal, not a promise of approval.
| Date / window | Ticker | Company | Event | Status | Sources |
|---|---|---|---|---|---|
| 2026-10-09 | $RHHBY | Roche | Tecentriq (atezolizumab) and Tecentriq Hybreza in combination with chemotherapy, adjuvant use — stage III colon cancer with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) status Priority review granted on data from the phase III ATOMIC study in 712 patients; Roche states the FDA is expected to decide by 9 October 2026. Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-10-15 | $RHHBY | Roche | Enspryng (satralizumab) — moderate-to-severe thyroid eye disease Priority Review based on SatraGO-1 and SatraGO-2. SatraGO-2 met its primary endpoint; SatraGO-1 did not reach statistical significance. Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-10-17 | $IRD | Opus Genetics, Inc. | MR-141, phentolamine ophthalmic solution 0.75% — presbyopia One sNDA shared by both partners, counted once. Sources: ; | Checked: 2026-09-19 | Confirmed date | Primary source Supporting source |
| 2026-10-17 | $VTRS | Viatris Inc. | MR-141, phentolamine ophthalmic solution 0.75% — presbyopia One sNDA shared by both partners, counted once. Sources: ; | Checked: 2026-09-19 | Confirmed date | Primary source Supporting source |
| 2026-10-26 | $IONS | IONIS PHARMACEUTICALS INC | Bepirovirsen, developed with GSK, for chronic hepatitis B. FDA goal October 26, 2026; one shared regulatory event already represented under IONS, not a new independent GSK deadline. | Confirmed date | Primary source Supporting source |
| 2026-10-30 | $INO | Inovio Pharmaceuticals, Inc. | INO-3107, DNA immunotherapy — recurrent respiratory papillomatosis in adults Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-01 | $AGIO | Agios Pharmaceuticals, Inc. | Pyrukynd (mitapivat) — sickle cell disease, accelerated approval pathway Sources: | Checked: 2026-09-19 | Program detail: PYRUKYND (mitapivat); NDA. | Confirmed date | Primary source |
| 2026-11-14 | $BTAI | BioXcel Therapeutics, Inc. | Igalmi (dexmedetomidine, sublingual film) — acute agitation in bipolar disorder or schizophrenia, at-home use Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-14 | $CYTK | CYTOKINETICS INC | aficamten — obstructive hypertrophic cardiomyopathy, extension based on the MAPLE-HCM trial Sources: | Checked: 2026-09-19 | Program detail: MYQORZO (aficamten). | Confirmed date | Primary source |
| 2026-11-14 | $SMMT | Summit Therapeutics Inc. | ivonescimab (SMT112) — EGFR-mutated non-squamous NSCLC, after TKI, in combination with chemotherapy Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-22 | $CAPR | CAPRICOR THERAPEUTICS, INC. | deramiocel (CAP-1002), cell therapy — Duchenne muscular dystrophy; refined proposed indication focused on upper limb function. FDA review of the BLA major amendment includes 24-month HOPE-3 open-label extension data and robustness analyses. On 24 August 2026 Capricor announced a three-month extension from 22 August to 22 November 2026. The target date is not an approval. | Confirmed date | Primary source |
| 2026-11-22 | $SVRA | Savara Inc. | Molbreevi (molgramostim), inhalation solution — autoimmune pulmonary alveolar proteinosis date extended by three months for a major amendment Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-25 | $SNY | Sanofi | venglustat, oral glucosylceramide synthase inhibitor — Gaucher disease type 3, neurological manifestations Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-27 | $BBIO | BridgeBio Pharma, Inc. | BBP-418 — limb-girdle muscular dystrophy LGMD2I/R9 Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-27 | $GSK | GSK | neladalkib (NVL-655) — advanced ALK-positive NSCLC, previously treated with TKI formerly a Nuvalent asset, acquired by GSK on 15 July 2026 Sources: ; | Checked: 2026-09-19 | Confirmed date | Primary source Supporting source |
| 2026-11-27 | $RPRX | Royalty Pharma plc | neladalkib — ALK-positive non-small cell lung cancer; royalty interest. FDA target action date: 2026-11-27. | Confirmed date | Primary source |
| 2026-11-28 | $PYPD | PolyPid Ltd. | D-PLEX100, local prolonged-release doxycycline depot — prevention of surgical site infections in colorectal surgery Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-30 | $COGT | Cogent Biosciences, Inc. | bezuclastinib, with sunitinib — gastrointestinal stromal tumours previously treated with imatinib Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-30 | $RHHBY | F. Hoffmann-La Roche Ltd | giredestrant — adjuvant treatment of ER-positive, HER2-negative early breast cancer, lidERA trial Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-30 | $VRTX | VERTEX PHARMACEUTICALS INCORPORATED | povetacicept, dual BAFF and APRIL inhibitor — IgA nephropathy, accelerated approval pathway Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-11-30 | $ZLAB | Zai Lab Limited | povetacicept — IgA nephropathy; Vertex partner. FDA target action date: 2026-11-30. | Confirmed date | Primary source |
| 2026-12-12 | $ANAB | ANAPTYSBIO, INC | imsidolimab — generalized pustular psoriasis; Vanda partner. FDA target action date: 2026-12-12. | Confirmed date | Primary source |
| 2026-12-12 | $VNDA | Vanda Pharmaceuticals Inc. | imsidolimab, IL-36R antagonist — generalized pustular psoriasis molecule originated by AnaptysBio, BLA held by Vanda Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-12-17 | $CORT | Corcept Therapeutics Incorporated | relacorilant, selective glucocorticoid receptor antagonist — Cushing's syndrome NDA resubmitted on 17 June 2026 after a CRL on this indication Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-12-18 | $CAMX | Camurus AB | CAM2029 (Oclaiz), acromegaly NDA resubmission: FDA target action date. CONFIRMED 2026-12-18. A review target is not an approval. Nasdaq Stockholm ticker CAMX. | Confirmed date | Primary source |
| 2026-12-18 | $RHHBY | F. Hoffmann-La Roche Ltd | giredestrant + everolimus — ER+/HER2− advanced or metastatic breast cancer with an ESR1 mutation, following progression on or after prior endocrine therapy Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-12-22 | $MLYS | Mineralys Therapeutics, Inc. | lorundrostat — hypertension in adults, in combination with other antihypertensives Sources: | Checked: 2026-09-19 | Program detail: lorundrostat; NDA. | Confirmed date | Primary source |
| 2026-12-23 | $GILD | GILEAD SCIENCES, INC. | anito-cel (anitocabtagene autoleucel), anti-BCMA CAR-T — relapsed or refractory multiple myeloma, fourth line BLA filed by Arcellx, acquired by Gilead on 28 April 2026 Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-12-27 | $PRAX | Praxis Precision Medicines, Inc. | relutrigine — SCN2A and SCN8A developmental and epileptic encephalopathies date extended from 27 September 2026 for a major amendment Sources: | Checked: 2026-09-19 | Program detail: relutrigine; NDA. | Confirmed date | Primary source |
| 2026-12-27 | $VTRS | Viatris Inc. | fast-acting meloxicam — moderate to severe acute pain, non-opioid analgesic Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 2026-12-30 | $COGT | Cogent Biosciences, Inc. | bezuclastinib monotherapy — non-advanced systemic mastocytosis Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 4 January 2027 | $NUVB | NUVATION BIO INC | PDUFA: IBTROZI (taletrectinib) · NSCLC advanced ROS1+ non-small cell lung cancer. Company timing: 4 January 2027. FDA target action date; approval is not assured. Primary source dated 2026-08-06; checked 2026-10-04. | Confirmed date | Primary source |
| 2027-01-06 | $IBRX | IMMUNITYBIO, INC. | ANKTIVA with BCG — BCG-unresponsive papillary-only non-muscle invasive bladder cancer. FDA target action date: 2027-01-06. | Confirmed date | Primary source |
| 2027-01-21 | $DYN | Dyne Therapeutics, Inc. | z-rostudirsen (DYNE-251) — Duchenne muscular dystrophy amenable to exon 51 skipping. FDA target action date: 2027-01-21. | Confirmed date | Primary source |
| 2027-01-29 | $PRAX | Praxis Precision Medicines, Inc. | ulixacaltamide — essential tremor. FDA target action date: 2027-01-29. | Confirmed date | Primary source |
| 2027-02-12 | $BLTE | BELITE BIO, INC | tinlarebant — Stargardt disease type 1. FDA target action date: 2027-02-12. | Confirmed date | Primary source |
| 2027-02-23 | $ARQT | Arcutis Biotherapeutics, Inc. | Zoryve cream 0.05% — atopic dermatitis, infants aged 3 to 24 months. FDA target action date: 2027-02-23. | Confirmed date | Primary source |
| 2027-02-27 | $CGEM | Cullinan Therapeutics, Inc. | zipalertinib — EGFR exon 20 insertion non-small cell lung cancer. FDA target action date: 2027-02-27. | Confirmed date | Primary source |
| 2027-02-28 | $APMD | Apnimed, Inc. | AD109 — obstructive sleep apnea. FDA target action date: 2027-02-28. | Confirmed date | Primary source |
| 2027-02-28 | $BMRN | BioMarin Pharmaceutical Inc. | Voxzogo (vosoritide) — full approval in children with achondroplasia. FDA target action date: 2027-02-28. | Confirmed date | Primary source |
| 2027-02-28 | $SRPT | Sarepta Therapeutics, Inc. | AMONDYS 45 and VYONDYS 53 — Duchenne muscular dystrophy; traditional approval conversion. FDA target action date: 2027-02-28. | Confirmed date | Primary source |
| 2027-03-03 | $EXEL | EXELIXIS, INC. | zanzalintinib + atezolizumab — previously treated metastatic colorectal cancer, STELLAR-303 New target March 3, 2027; December 3, 2026 is no longer an active deadline. FDA notified the company on September 10 that new safety and efficacy data constituted a major amendment; filing dated September 11. Sources: | Checked: 2026-09-19 | Confirmed date | Primary source |
| 10 March 2027 | $NTLA | INTELLIA THERAPEUTICS INC | PDUFA: lonvoguran ziclumeran (also referred to as NTLA-2002) · HAE Hereditary Angioedema (HAE) (NDA). Company timing: 10 March 2027. FDA target action date; approval is not assured. Primary source dated 2026-09-08; checked 2026-10-04. | Confirmed date | Primary source |
| 2027-03-10 | $NTLA | Intellia Therapeutics, Inc. | lonvo-z (NTLA-2002), HAE. BLA accepted with Priority Review; FDA target action date, not approval. | Confirmed date | Primary source |
| 2027-03-11 | $BMY | BRISTOL MYERS SQUIBB | Reblozyl (luspatercept) — myelofibrosis-associated anemia. FDA target action date: 2027-03-11. | Confirmed date | Primary source |
| 2027-03-22 | $MRK | Merck & Co., Inc. | Enflonsia (clesrovimab-cfor) — children entering a second RSV season at increased risk. FDA target action date: 2027-03-22. | Confirmed date | Primary source |
| 2027-04-01 | $HRMY | Harmony Biosciences Holdings, Inc. | pitolisant GR — narcolepsy. FDA target action date: 2027-04-01. | Confirmed date | Primary source |
| 14 April 2027 | $INBX | INHIBRX BIOSCIENCES INC | PDUFA: ozekibart (INBRX-109) · Conventional chondrosarcoma. Company timing: 14 April 2027. FDA target action date; approval is not assured. Primary source dated 2026-08-13; checked 2026-10-04. | Confirmed date | Primary source |
| 2027-04-23 | $PHVS | Pharvaris N.V. | deucrictibant IR — on-demand treatment of hereditary angioedema attacks. FDA target action date: 2027-04-23. | Confirmed date | Primary source |
| 2027-04-23 | $RPRX | Royalty Pharma plc | deucrictibant IR — hereditary angioedema; royalty interest. FDA target action date: 2027-04-23. | Confirmed date | Primary source |
| 2027-04-24 | $ORGO | Organogenesis Holdings Inc. | ReNu — symptomatic knee osteoarthritis. FDA target action date: 2027-04-24. | Confirmed date | Primary source |
| 2027-04-28 | $IMNM | IMMUNOME, INC. | varegacestat — desmoid tumors in adults. FDA target action date: 2027-04-28. | Confirmed date | Primary source |
| 2027-05-01 | $AXSM | Axsome Therapeutics, Inc. | AXS-12 (reboxetine) — narcolepsy. FDA target action date: 2027-05-01. | Confirmed date | Primary source |
| 2027-05-08 | $BBIO | BridgeBio Pharma, Inc. | encaleret — autosomal dominant hypocalcemia type 1. FDA target action date: 2027-05-08. | Confirmed date | Primary source |
| 2027-05-13 | $BMY | BRISTOL MYERS SQUIBB | mezigdomide with carfilzomib and dexamethasone — relapsed/refractory multiple myeloma. FDA target action date: 2027-05-13. | Confirmed date | Primary source |
| 2027-05-27 | $ZBIO | Zenas BioPharma, Inc. | obexelimab — IgG4-related disease. FDA target action date: 2027-05-27. | Confirmed date | Primary source |
| 2027-06-24 | $UTHR | UNITED THERAPEUTICS CORPORATION | ralinepag — pulmonary arterial hypertension. FDA target action date: 2027-06-24. | Confirmed date | Primary source |
| 2027-06-29 | $COGT | Cogent Biosciences | Bezuclastinib NDA in advanced systemic mastocytosis (AdvSM): FDA target action date June 29, 2027, announced September 15. Separate from GIST November 30 and nonadvanced SM December 30, 2026. Approval is not assured. | Confirmed date | Primary source |
| Date / window | Ticker | Company | Event | Status | Sources |
|---|---|---|---|---|---|
| 2026-10-05 | $BLFS | BioLife Solutions / Repligen | BioLife shareholder vote on Repligen merger, 09:00 ET / 15:00 Europe/Rome. Closing remains conditional. | Confirmed date | Primary source |
| 2026-10-08 | $BBIO | BridgeBio Pharma | Commercial Day in New York City: commercial readiness and launch strategy across three planned launches. Corporate event, not an FDA decision. Time not specified in the source. | Confirmed date | Primary source |
| 9 October 2026 | $ANIP | ANI PHARMACEUTICALS INC | SYNCHRONICITY Phase 4 results for fluocinolone acetonide intravitreal implant in chronic non-infectious posterior-segment uveitis: late-breaking oral presentation at AAO Uveitis Subspecialty Day, October 9 at 4:50 p.m. ET. NEW DAY post-hoc analyses in diabetic macular edema will also be available as an on-demand ePoster; a separate poster day is not specified. Company timing: 9 October 2026. Congress: AAO Annual Meeting. Primary source dated 2026-09-30; checked 2026-10-04. | Confirmed date | Primary source Supporting source |
| 2026-10-20 | $ANAB | AnaptysBio | Post-trial hearing in GSK/Tesaro Jemperli litigation. Hearing date is not judgment date. | Confirmed date | Primary source |
| 2026-10-23 | $ALNY | Alnylam Pharmaceuticals, Inc. | ALN-HTT02 Phase 1 initial results at EHDN; presentation date October 23, 2026 announced in Q2 results. | Confirmed date | Primary source |
| 2026-10-24 | $CMPX | Compass Therapeutics, Inc. | COMPANION-002 tovecimig oral presentation at ESMO 2026. CONFIRMED DATE, presentation time not confirmed here. Compass Therapeutics will present results of the randomized Phase 2/3 COMPANION-002 trial of tovecimig plus paclitaxel in advanced biliary tract cancer at ESMO on 24 October 2026. | Confirmed date | Primary source |
| 24 October 2026 | $PBLS | PARABILIS MEDICINES INC | Conference presentation: zolucatetide · desmoid tumor (Phase 1/2). Company timing: 24 October 2026. Congress: ESMO Congress. Primary source dated 2026-09-15; checked 2026-10-04. | Confirmed date | Primary source Congress schedule |
| 25 October 2026 | $ANAB | ANAPTYSBIO INC | Conference presentation: Jemperli (dostarlimab) · Untreated stage II/III dMMR/MSI-H locally advanced rectal cancer AZUR-1 (pivotal Phase 2). Company timing: 25 October 2026. Congress: ESMO Congress. Primary source dated 2026-09-21; checked 2026-10-04. | Confirmed date | Primary source Congress schedule |
| 2026-10-25 | $GSK | GSK / AnaptysBio | AZUR-1 dostarlimab Phase 2 first-results presentation at ESMO, Madrid; distinct from FDA review. | Confirmed date | Primary source |
| 2026-10-25 | $SMMT | Summit Therapeutics / Akeso | HARMONi-GI1 Phase 3 biliary-tract cancer presentation, ESMO Presidential Symposium II, LBA8. Session 16:30-18:15 CET / 11:30-13:15 EDT; individual talk time not announced. Akeso-sponsored study conducted in China. Separate from the November 14 NSCLC PDUFA. | Confirmed date | Primary source |
| 2 November 2026 | $RXRX | RECURSION PHARMACEUTICALS INC | Conference presentation: REC-4881 · Familial adenomatous polyposis. Company timing: 2 November 2026. Congress: CGA-IGC Annual Meeting. Primary source dated 2026-08-05; checked 2026-10-04. | Confirmed date | Primary source Supporting source |
| November 8, 2026 | $CGEM | Cullinan Therapeutics, Inc. | Velinotamig: multidose data from the Genrix Bio Phase 1 dose-escalation study in systemic lupus erythematosus, poster presentation at ACR Convergence on November 8, 2026, 10:30 a.m.–12:30 p.m. Eastern. | Confirmed date | Primary source |
| 8 November 2026 | $MLYS | MINERALYS THERAPEUTICS INC | Transform-HTN open-label extension: long-term efficacy and safety of lorundrostat in uncontrolled hypertension. Late-breaking AHA Scientific Sessions presentation on November 8 at 3:30 p.m. CT, Chicago. This is a clinical presentation, separate from the December PDUFA target. Company timing: 8 November 2026. Congress: AHA Scientific Sessions. Primary source dated 2026-09-23; checked 2026-10-04. | Confirmed date | Primary source Supporting source |
| November 9, 2026 | $ARTV | Artiva Biotherapeutics, Inc. | AlloNK (AB-101) plus rituximab updated Phase 2a basket data in refractory RA, Sjögren disease and systemic sclerosis at ACR 2026. Oral session November 9, 3:00-4:30 pm EST; investor webcast 8:15 am EST. | Confirmed date | Primary source |
| November 10, 2026 | $ARTV | Artiva Biotherapeutics, Inc. | AlloNK (AB-101) plus rituximab safety and B-cell depletion data from a 60-patient rheumatology cohort, ACR poster 2384 November 10, 10:30 am-12:30 pm EST. Separate poster from the November 9 oral efficacy update; overlapping patients are possible. | Confirmed date | Primary source |
The range refers to the conference dates. Any confirmed individual presentation day is stated in the row; other presentation days are not inferred from the conference start.
| Date / window | Ticker | Company | Event | Status | Sources |
|---|---|---|---|---|---|
| 8–11 October 2026 | $ATTO | ATTOVIA THERAPEUTICS INC | ATTO-1310 Phase 1b interim efficacy and safety poster in atopic dermatitis or chronic pruritus at Fall Clinical Dermatology Conference. The EADV posters concern separate healthy-volunteer and translational datasets. Company timing: 8–11 October 2026. Congress: Fall Clinical Dermatology Conference 2026. The conference range does not establish the individual presentation day. Primary source dated 2026-09-28; checked 2026-10-04. | Conference range | Primary source |
| 8–11 October 2026 | $ATTO | ATTOVIA THERAPEUTICS INC | Preclinical characterization of ATTO-2306, a long-acting bispecific antibody targeting IL-13 and IL-31, presented at Fall Clinical Dermatology Conference. Company timing: 8–11 October 2026. Congress: Fall Clinical Dermatology Conference 2026. The conference range does not establish the individual presentation day. Primary source dated 2026-09-28; checked 2026-10-04. | Conference range | Primary source |
| ECNP Congress 2026-10-10–2026-10-13 | $GHRS | GH RESEARCH PLC | Conference presentation: mebufotenin (GH001) · TRD Treatment-resistant depression (Phase 2b). Company timing: ECNP Congress 2026-10-10–2026-10-13. Congress: ECNP Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-06; checked 2026-10-04. | Conference range | Primary source Trial registry Congress schedule |
| 15–16 October 2026 | $TSHA | TAYSHA GENE THERAPIES INC | TSHA-102 REVEAL Part A Phase 1/2 safety and efficacy results in Rett syndrome: encore oral and poster presentations on October 15 at the Child Neurology Society meeting. Company-hosted symposium on October 16. These sessions repeat previously shared IRSF data rather than announce a new readout. Company timing: 15–16 October 2026. Primary source dated 2026-10-01; checked 2026-10-04. | Estimated window | Primary source |
| UEG Week 2026-10-17–2026-10-20 | $ABVX | ABIVAX SA | Conference presentation: obefazimod. Company timing: UEG Week 2026-10-17–2026-10-20. Congress: UEG Week. The conference range does not establish the individual presentation day. Primary source dated 2026-09-21; checked 2026-10-04. | Conference range | Primary source Supporting source |
| October 21-23, 2026 conference; presentation day unspecified | $KYTX | Kyverna Therapeutics, Inc. | KYSA-8 miv-cel full one-year dataset presentation at MS Toronto. CONFIRMED October 21-23, 2026 conference; presentation day unspecified. October 21 is the conference-start marker, not a confirmed presentation day. Exclude from exact-day confirmed table unless range can be displayed explicitly. | Estimated window | Primary source |
| MSToronto Joint ACTRIMS-ECTRIMS Congress 2026-10-21–2026-10-23 | $ZBIO | ZENAS BIOPHARMA INC | Conference presentation: orelabrutinib. Company timing: MSToronto Joint ACTRIMS-ECTRIMS Congress 2026-10-21–2026-10-23. Congress: MSToronto Joint ACTRIMS-ECTRIMS Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-13; checked 2026-10-04. | Conference range | Primary source Supporting source |
| ESMO Congress 2026-10-23–2026-10-27 | $BHVN | BIOHAVEN LTD | Conference presentation: BHV-1530 · Advanced solid tumors (Phase 1). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-10; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $GENB | GENERATE BIOMEDICINES INC | Conference presentation: GB-4362 · locally advanced or metastatic urothelial cancer (Phase 1). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-06; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $HCM | HUTCHMED (CHINA) LTD | Conference presentation: ORPATHYS (savolitinib) plus TAGRISSO (osimertinib). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-09-29; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $HCM | HUTCHMED (CHINA) LTD | SANOVO Phase III savolitinib plus osimertinib results selected for an oral Proffered Paper presentation at ESMO. Separate from the SAFFRON Presidential Symposium presentation. Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-09-24; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $IDYA | IDEAYA BIOSCIENCES INC | Conference presentation: IDE849 (DLL3 TOP1i ADC) · SCLC small-cell lung cancer (SCLC) and neuroendocrine carcinomas (NEC) (Phase 1). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-04; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $IDYA | IDEAYA BIOSCIENCES INC | Conference presentation: darovasertib combination (Phase 2). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-04; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $IDYA | IDEAYA BIOSCIENCES INC | Conference presentation: darovasertib · Primary uveal melanoma; Metastatic uveal melanoma. Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-04; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $INBX | INHIBRX BIOSCIENCES INC | Conference presentation: INBRX-106 · HNSCC locally advanced recurrent or metastatic HNSCC; Head and neck squamous cell carcinoma The data were reported in a filing of Sep 8, 2026; this slot presents them. (Phase 2). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-03-19; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $IOVA | IOVANCE BIOTHERAPEUTICS INC | Conference presentation: Amtagvi (lifileucel) · UPS and DDLPS (registrational). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-06; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $ORIC | ORIC PHARMACEUTICALS INC | Conference presentation: enozertinib · 1L NSCLC with EGFR atypical mutations. Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-03; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $TNGX | TANGO THERAPEUTICS INC | Conference presentation: vopimetostat · PDAC Pancreatic cancer (Phase 1/2). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-11; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $XNCR | XENCOR INC | Conference presentation: XmAb819 · RCC Clear cell renal cell carcinoma (Phase 1). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-05; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| ESMO Congress 2026-10-23–2026-10-27 | $ZLAB | ZAI LAB LTD | Conference presentation: zocilurtatug pelitecan · SCLC first-line SCLC; Extensive-Stage Small Cell Lung Cancer (Phase 1). Company timing: ESMO Congress 2026-10-23–2026-10-27. Congress: ESMO Congress. The conference range does not establish the individual presentation day. Primary source dated 2026-08-06; checked 2026-10-04. | Conference range | Primary source Congress schedule |
| November 16-19, 2026 conference; presentation day unspecified | $ACAD | Acadia Pharmaceuticals Inc. | RADIANT Phase 2 remlifanserin detailed safety and efficacy oral presentation at CTAD. CONFIRMED November 16-19, 2026 conference; presentation day unspecified. November 16 is the conference-start marker, not a confirmed presentation day. Primary endpoint was not statistically met. Exclude from exact-day confirmed table unless conference range is explicit. | Conference range | Primary source Supporting source |
Quarters, half-years and other windows are company guidance, not exact dates. Estimates derived from a regulatory review duration are labeled as calculated. A window-end marker is not an announced readout day. Filings, study starts and results are different milestones.
| Date / window | Ticker | Company | Event | Status | Sources |
|---|---|---|---|---|---|
| October 2026 | $IVVD | Invivyd, Inc. | VYD2311 DECLARATION placebo-controlled safety and neutralizing-antiviral-titer topline expected in October 2026. This is a month window and 31 October is a conventional end marker, not a company-announced day. Clinical efficacy events remain blinded and a BLA is only planned, subject to supportive data. | Estimated window | Primary source |
| October 2026 | $MIRM | Mirum Pharmaceuticals / Incyte | Atebrioz US commercial launch expected October 2026; exact day not announced. ESTIMATED window: October 2026. | Estimated window | Primary source |
| October 2026 | $PCVX | VAXCYTE INC | Topline data: VAX-31 OPUS-1. Company timing: October 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-03; checked 2026-10-04. | Estimated window | Primary source |
| October 2026 | $RAPP | RAPPORT THERAPEUTICS INC | Topline data: RAP-219 · Bipolar mania (Phase 2). Company timing: October 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| October 2026 | $TLSA | Tiziana Life Sciences Ltd. | INFORM-MS foralumab 12-week topline. ESTIMATED window: October 2026. 2026-10-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| October 2026 | $TRDA | TRDA | ENTR-601-45: ELEVATE-45-201 Cohort 1 multiple-ascending-dose data (5 mg/kg) in exon-45-skipping-amenable Duchenne muscular dystrophy, expected in October 2026. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| Around November 1, 2026 (calculated) | $QURE | uniQure N.V. | AMT-130 BLA filing-review decision window. ESTIMATED Around November 1, 2026 (calculated). November 1 is calculated from 60 calendar days after the September 2 submission; the issuer did not announce an exact decision day. Priority review was requested, not granted. This is not a PDUFA deadline. | Estimated window | Primary source |
| ACAAI Annual Scientific Meeting 2026-11-12–2026-11-16 | $ADMA | ADMA BIOLOGICS INC | ASCENIV real-world outcomes abstract submitted to ACAAI. Acceptance and an individual presentation date are not confirmed by the cited release. Company timing: ACAAI Annual Scientific Meeting 2026-11-12–2026-11-16. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Congress: ACAAI Annual Scientific Meeting. The conference range does not establish the individual presentation day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source Supporting source |
| 17 October–16 November 2026 | $RARE | Ultragenyx Pharmaceutical Inc. | FAYUVI commercial product expected available to ship to qualified treatment centers within 30-60 days of September 17 approval: October 17-November 16, 2026. November 16 is a conventional end-of-window marker, not a confirmed shipment date, patient treatment or recognized revenue. | Estimated window | Primary source |
| September–November 2026 | $ACAD | ACADIA PHARMACEUTICALS INC | Topline data: DAYBUE (trofinetide) · RTT Rett syndrome. Company timing: September–November 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| End of November 2026 | $MLTX | MoonLake Immunotherapeutics | Sonelokimab HS BLA acceptance, Priority Review decision and PDUFA date allocation. ESTIMATED End of November 2026. Conditional on planned filing; November 30 is an indicative marker, not an announced PDUFA date. | Estimated window | Primary source Supporting source |
| November 2026 | $RHHBY | Roche Holding AG | Gazyva/Gazyvaro (obinutuzumab): FDA decision window in primary membranous nephropathy. ESTIMATED November 2026. Priority Review is confirmed, but the issuer states November, not a specific day. | Estimated window | Primary source |
| Late November 2026 | $SLGL | Sol-Gel Technologies Ltd. | SGT-610 (patidegib gel 2%), pivotal Phase 3 in Gorlin syndrome. September 17 company update reports last patient last visit and expects topline results in late November 2026. November 30 is a conventional end-of-window marker, not an exact readout date. Registry completion is a separate milestone. | Estimated window | Primary source |
| 2026 | $AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | Initial data: APG-3288 (Phase 1). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-01-15; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ABCL | ABCELLERA BIOLOGICS INC | Topline data: ABCL575 (Phase 1). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ABSI | ABSCI CORP | Interim data: ABS-201 · PHL. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $ABVX | ABIVAX SA | NDA/BLA submission: obefazimod · UC Ulcerative colitis (Phase 3). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-21; checked 2026-10-04. | Estimated window | Primary source |
| By year-end 2026 | $ADMA | ADMA BIOLOGICS INC | FDA meeting: SG-001 · Streptococcus pneumoniae infection. Company timing: By year-end 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $AGIO | AGIOS PHARMACEUTICALS INC | Topline data: tebapivat · SCD Sickle Cell Disease (Phase 2). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-04-29; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $AGIO | AGIOS PHARMACEUTICALS INC | Initial data: AG-181 · PKU Phenylketonuria (PKU) (Phase 1b). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $ALKS | ALKERMES PLC | NDA/BLA submission: LUMRYZ (sodium oxybate) · Idiopathic hypersomnia (Phase 3). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-12; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $ALKS | ALKERMES PLC | Topline data: alixorexton · Idiopathic hypersomnia (phase 2). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-28; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ALNY | Alnylam Pharmaceuticals, Inc. | ALN-6400 Phase 1/2 and ALN-2232 Phase 1 readouts expected H2 2026; October 1 is an indicative placement, not an announced clinical date. | Estimated window | Primary source |
| Late 2026 | $ALVO | ALVOTECH | Potential regulatory decision (company forecast): Biologics License Applications. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-19; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $ALVO | ALVOTECH | Regulatory decision: relevant BLAs. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-11; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $AMLX | AMYLYX PHARMACEUTICALS INC | NDA/BLA submission: avexitide · Post-bariatric hypoglycemia. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-18; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ANIP | ANI PHARMACEUTICALS INC | Topline data: ILUVIEN · chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) SYNCHRONICITY (Phase 4). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| By year-end 2026 | $ARCT | Arcturus Therapeutics Holdings Inc. | ARCT-2601 integration into the ongoing OTC-deficiency Phase 2 study. ESTIMATED By year-end 2026. Company plan following the September 23 ARCT-810 interim announcement; regulatory and operational execution remain prospective. | Estimated window | Primary source |
| Q4 2026 | $ARQT | ARCUTIS BIOTHERAPEUTICS INC | Clinical data readout: ZORYVE foam 0.3% · Vitiligo (Phase 2). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $ARWR | ARROWHEAD PHARMACEUTICALS INC | NDA/BLA submission: REDEMPLO (plozasiran) · sHTG severe hypertriglyceridemia (sHTG). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ATAI | ATAIBECKLEY INC | Initial data: BPL-003 · TRD treatment-resistant depression (TRD) (Phase 2a). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-12; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ATAI | ATAIBECKLEY INC | Topline data: VLS-01 · TRD (Phase 2). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-12; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $AVBP | ARRIVENT BIOPHARMA INC | ARR-217 Phase 1 dose-escalation completion and transition to dose optimization. No interim-results publication is promised by this milestone. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $AVBP | ARRIVENT BIOPHARMA INC | Topline data: firmonertinib · first-line EGFR exon 20 insertion mutant NSCLC (Phase 3). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q4 2026 | $AXSM | AXSOME THERAPEUTICS INC | Topline data: solriamfetol · Binge eating disorder ENGAGE (Phase 3). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $BCAX | BICARA THERAPEUTICS INC | Initial data: ficerafusp alfa · 3L+ mCRC (RAS/BRAF wild type MSS); mCRC (RAS/BRAF wild type MSS) (Phase 1b). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-11; checked 2026-10-04. | Estimated window | Primary source |
| by end of 2026 | $BCRX | BioCryst Pharmaceuticals, Inc. | BCX17725 Phase 1 Part 4 data in Netherton syndrome. ESTIMATED by end of 2026. Up to 12 patients followed for three months; no exact release day. | Estimated window | Primary source |
| 2026 | $BEAM | BEAM THERAPEUTICS INC | Full data: BEAM-302 · AATD alpha-1 antitrypsin deficiency (AATD). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $BEAM | BEAM THERAPEUTICS INC | Clinical data readout: ristoglogene autogetemcel (risto-cel) · SCD sickle cell disease (SCD) BEACON (Phase 1/2). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $BEAM | BEAM THERAPEUTICS INC | Initial data: BEAM-301 · glycogen storage disease type Ia (GSDIa) (Phase 1/2). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $BHVN | BIOHAVEN LTD | Topline data: opakalim · Focal epilepsy (pivotal). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $BHVN | BIOHAVEN LTD | Topline data: taldefgrobep alfa · Obesity (Phase 2). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $BIOA | BioAge Labs, Inc. | QUELL-CV BGE-102 Phase 2 topline in cardiovascular risk. ESTIMATED H2 2026. December 31 is an indicative marker. Enrollment completed; timing guidance reaffirmed September 8. | Estimated window | Primary source Supporting source |
| Q4 2026 | $CELC | CELCUITY INC | Clinical data readout: REVTORPYK (gedatolisib) · Metastatic castration-resistant prostate cancer (Phase 2). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| December 2026 | $CGEM | Cullinan Therapeutics, Inc. | CLN-049: updated Phase 1 dose-escalation data with longer follow-up in relapsed/refractory acute myeloid leukemia, expected in December 2026. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| December 2026 | $CGEM | Cullinan Therapeutics, Inc. | CLN-978: concurrent multidose and single-target-dose clinical data in systemic lupus erythematosus, rheumatoid arthritis and Sjögren's disease, expected in December 2026. One planned package across three indications. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| 2026 | $CGON | CG ONCOLOGY INC | BOND-003 Cohort P durability data in high-risk BCG-unresponsive Ta/T1 non-muscle-invasive bladder cancer without carcinoma in situ. Cohort C and CORE-008 Cohort A data are represented separately. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-27; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $CGON | CG ONCOLOGY INC | NDA/BLA submission: cretostimogene · HR BCG-unresponsive NMIBC. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $CLDX | CELLDEX THERAPEUTICS INC | Topline data: barzolvolimab · AtD Atopic dermatitis (Phase 2). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $CLYM | Climb Bio, Inc. | CLYM116 additional Phase 1 and Mabworks initial healthy-volunteer data. ESTIMATED Q4 2026. Planned for a medical meeting in Q4; meeting and presentation date not named. December 31 is a window-end marker. | Estimated window | Primary source Supporting source |
| 2026 | $COGT | COGENT BIOSCIENCES INC | IND submission: CGT1145. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-05; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $COGT | COGENT BIOSCIENCES INC | Initial data: CGT4859 (Phase 1). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-17; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $COGT | COGENT BIOSCIENCES INC | IND submission: CGT1815 · Cancer. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $COGT | COGENT BIOSCIENCES INC | Preliminary results from the SUMMIT extension cohort switching patients from avapritinib to bezuclastinib. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $CRSP | CRISPR Therapeutics AG | CTX310 Phase 1b severe hypertriglyceridemia cohort clinical update. ESTIMATED H2 2026. Distinct from the Phase 1a one-year durability data already presented at ESC on August 28. | Estimated window | Primary source |
| H2 2026 | $CRSP | CRISPR THERAPEUTICS AG | Clinical data readout: CTX611 (SRSD107) · Thromboembolic and clotting-related indications (Phase 2). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $CRSP | CRISPR THERAPEUTICS AG | Clinical data readout: zugocabtagene geleucel (zugo-cel; formerly CTX112™) · SLE B-cell malignancies; systemic lupus erythematosus, systemic sclerosis, inflammatory myositis, immune thrombocytopenic purpura, and warm autoimmune hemolytic anemia (Phase 1/2). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-04; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $CRSP | CRISPR THERAPEUTICS AG | Preclinical program update: CTX321™ · elevated lipoprotein(a) [Lp(a)]. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-12; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $CYTK | CYTOKINETICS INC | NDA/BLA submission: MYQORZO (aficamten) · symptomatic nHCM (Phase 3). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-28; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $DFTX | DEFINIUM THERAPEUTICS INC | Initial data: MM402 (R(-)-MDMA) · Autism Spectrum Disorder (Phase 2a). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-19; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $DFTX | Definium Therapeutics | DT120 ODT — pre-NDA meeting scheduled in Q4 2026. December 31 is the conventional end of the October–December window, not the exact meeting date. | Estimated window | Primary source |
| H2 2026 | $DMRA | DAMORA THERAPEUTICS INC | IND submission: DMR-002. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $DMRA | DAMORA THERAPEUTICS INC | Regulatory submissions to expand the Phase 1/1b DMR-001 trial globally in essential thrombocythemia and myelofibrosis. These are trial authorizations, not marketing applications. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| December 2026 | $DNTH | DIANTHUS THERAPEUTICS INC | Topline data: claseprubart · Multifocal motor neuropathy (Phase 2). Company timing: December 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $DNTH | DIANTHUS THERAPEUTICS INC | Initial data: DNTH212 · SLE Systemic Lupus Erythematosus (Phase 1). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $DRTS | ALPHA TAU MEDICAL LTD | PMA submission: Alpha DaRT · cutaneous squamous cell carcinoma ReSTART. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-01-29; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 | $DRTS | ALPHA TAU MEDICAL LTD | Interim data: Alpha DaRT · GBM glioblastoma multiforme REGAIN. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ELDN | Eledon Pharmaceuticals, Inc. | LEGACY Phase 3 kidney-transplant trial initiation. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| H2 2026 | $ERAS | ERASCA INC | Initial data: ERAS-4001 · RAS-mutant solid tumors (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ETON | ETON PHARMACEUTICALS INC | Topline data: ET-700 · Wilson disease. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-14; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $ETON | ETON PHARMACEUTICALS INC | NDA/BLA submission: AMGLIDIA®. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $EWTX | EDGEWISE THERAPEUTICS INC | GRAND CANYON pivotal cohort topline results in Becker muscular dystrophy. Servier acquired sevasemten and the muscular-dystrophy business in July 2026; Edgewise retains exposure through contingent milestone payments. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Servier-owned program; EWTX contingent milestone exposure. Primary source dated 2026-07-13; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| later in 2026 | $GOSS | Gossamer Bio, Inc. | FDA filing-acceptance review of seralutinib NDA. ESTIMATED later in 2026. Issuer expects this could occur later this year. No PDUFA announced; timing is not a guaranteed Q4 appointment. | Estimated window | Primary source |
| Q4 2026 | $GPCR | STRUCTURE THERAPEUTICS INC | Results from the Phase 2 aleniglipron study in adults with type 2 diabetes and obesity or overweight. Separate from the 44-week body-composition study. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q4 2026 | $GPCR | STRUCTURE THERAPEUTICS INC | Results from the 44-week Phase 2 body-composition trial of aleniglipron, evaluating body fat and overall body composition. This is separate from the Phase 2 diabetes study. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q4 2026 | $GRFS | GRIFOLS SA | Topline data: alpha-1 antitrypsin · Emphysema SPARTA (Phase 3). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-29; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $HCM | HUTCHMED (CHINA) LTD | Clinical trial initiation: HMPL-A830 · Solid tumors. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $HCM | HUTCHMED (CHINA) LTD | IND submission: ATTC candidates. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2025-10-23; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Topline data: BP-205 (Phase 1). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $HROW | HARROW INC | Topline data: NATACYN · fungal keratitis. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $HROW | HARROW INC | Topline data: IHEEZO · patients undergoing intravitreal injections QUELL (Phase 4). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IDYA | IDEAYA BIOSCIENCES INC | NDA/BLA submission: darovasertib in combination with crizotinib · Metastatic uveal melanoma (registrational). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $IDYA | IDEAYA BIOSCIENCES INC | Conference presentation: IDE397 · MTAP-deleted urothelial cancer (UC) (Phase 1/2). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-17; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $IMCR | IMMUNOCORE HOLDINGS PLC | Topline data: KIMMTRAK (tebentafusp) · previously treated advanced melanoma. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-14; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IMCR | IMMUNOCORE HOLDINGS PLC | IND submission: IMC-U120AI · AtD Atopic dermatitis; autoimmune candidate. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IMCR | IMMUNOCORE HOLDINGS PLC | Conference presentation: IMC-P115C · solid tumors; Multiple solid tumors (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IMCR | IMMUNOCORE HOLDINGS PLC | Conference presentation: brenetafusp · solid tumors; ovarian and lung cancer (Phase 1/2). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $IMNM | IMMUNOME INC | IND submission: IM-1335. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $IMNM | IMMUNOME INC | IND submission: solid tumor-targeted ADC programs · Solid tumors. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-03; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $IMNM | IMMUNOME INC | Initial data: IM-1021 · B-cell lymphoma (Phase 1). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $IMNM | IMMUNOME INC | Marketing authorization application: varegacestat (formerly AL102). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IMTX | IMMATICS NV | Initial data: IMA402 · melanoma and gynecologic cancers (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IMTX | IMMATICS NV | Clinical data readout: IMA203CD8 · Gynecologic cancers (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-06-01; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H2 2026 | $IMVT | IMMUNOVANT INC | Clinical program update: imeroprubart (IMVT-1402) · RA Difficult-to-treat rheumatoid arthritis (potentially registrational). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H2 2026 | $IMVT | IMMUNOVANT INC | Topline data: imeroprubart (IMVT-1402) · RA Cutaneous lupus erythematosus; Rheumatoid arthritis. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q4 2026 | $INBX | INHIBRX BIOSCIENCES INC | FDA meeting: ozekibart (INBRX-109) · CRC Colorectal cancer (Phase 1). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $IOVA | IOVANCE BIOTHERAPEUTICS INC | Conference presentation: Amtagvi (lifileucel) · metastatic non-squamous NSCLC. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $IOVA | IOVANCE BIOTHERAPEUTICS INC | Regulatory decision: Amtagvi (lifileucel) · Advanced melanoma. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $IPHA | Innate Pharma S.A. | PACIFIC-9 Phase 3 monalizumab readout. ESTIMATED window: H2 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Late 2026 | $IRON | DISC MEDICINE INC | Initial data: DISC-3405 · SCD Sickle cell disease (Phase 1b). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-10; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $IRON | DISC MEDICINE INC | FDA meeting: selcodebart (DISC-0974) · anemia of MF (Phase 2). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-10; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $IRON | DISC MEDICINE INC | Topline data: bitopertin · EPP. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $IVA | Inventiva S.A. | NATiV3 Phase 3 lanifibranor topline in MASH. ESTIMATED Q4 2026. Last patient visit completed; exact readout day unannounced. | Estimated window | Primary source |
| 2026 | $JANX | JANUX THERAPEUTICS INC | Full data: JANX008 · Solid tumors (Phase 1). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-26; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $JANX | Janux Therapeutics, Inc. | JANX011 Phase 1 initial clinical data in healthy volunteers. ESTIMATED H2 2026. December 31 is an indicative marker. Healthy-volunteer data are not efficacy data in autoimmune patients. | Estimated window | Primary source |
| Q4 2026 | $KOD | Kodiak Sciences | Zenkuda multi-indication BLA submission planned. ESTIMATED window: Q4 2026. Five positive Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion. This is a planned submission, not an accepted filing, approval or PDUFA date. | Estimated window | Primary source |
| December 2026 | $KOD | Kodiak Sciences | KSI-101 PEAK Phase 3 Pivotal Analysis 1 topline in macular edema secondary to inflammation, first 300-patient cohort. ESTIMATED window: December 2026. No exact release day; separate from registry primary completion and Pivotal Analysis 2. | Estimated window | Primary source Supporting source |
| Late 2026 | $KRYS | KRYSTAL BIOTECH INC | Interim data: KB407 · CF Cystic Fibrosis (Phase 1). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H2 2026 | $KRYS | KRYSTAL BIOTECH INC | NDA/BLA submission: VYJUVEK (beremagene geperpavec) · Dystrophic Epidermolysis Bullosa. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $KRYS | KRYSTAL BIOTECH INC | Topline data: beremagene geperpavec-svdt (KB803) · corneal abrasions in DEB patients (registrational). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 | $KRYS | KRYSTAL BIOTECH INC | Topline data: KB801 · Neurotrophic keratitis (registrational). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-04; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q4 2026 | $KRYS | KRYSTAL BIOTECH INC | FDA meeting: KB407 · CF Cystic fibrosis (registrational). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 | $KRYS | KRYSTAL BIOTECH INC | FDA meeting: KB111 · Hailey-Hailey disease (HHD). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $KRYS | KRYSTAL BIOTECH INC | Interim data: KB707 · Gorlin syndrome (Phase 1/2). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 | $KRYS | KRYSTAL BIOTECH INC | Interim data: KB111 · Hailey-Hailey Disease. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 | $KYMR | KYMERA THERAPEUTICS INC | Topline data: KT-621 · AtD Atopic dermatitis (Phase 2b). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-06-25; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $KYMR | KYMERA THERAPEUTICS INC | Clinical data readout: KT-579 (Phase 1). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $KYTX | Kyverna Therapeutics, Inc. | miv-cel rolling BLA submission completion in SPS. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| H2 2026 | $LEGN | LEGEND BIOTECH CORP | Initial data: dual CD20/CD19-targeted cell therapy. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-01-12; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $LGND | LIGAND PHARMACEUTICALS INC | NDA/BLA submission: Qtorin 3.9% rapamycin anhydrous gel (Qtorin rapamycin) · microcystic lymphatic malformations (microcystic LMs); MLM. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $LGND | LIGAND PHARMACEUTICALS INC | Topline data: ersodetug · Tumor hyperinsulinism (Phase 3). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $LQDA | LIQUIDIA CORP | Planned completion of the ASCENT open-label study assessing 52 weeks of YUTREPIA treatment in pulmonary hypertension associated with interstitial lung disease. Completion is not an announced public data-release date. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-01-09; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $MANE | VERADERMICS INC | Topline data: VDPHL01 · Male pattern hair loss (Phase 3). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $MBX | MBX BIOSCIENCES INC | First-cohort results from the 12-week multiple-ascending-dose portion of the Phase 1 MBX 4291 obesity trial. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $MBX | MBX BIOSCIENCES INC | Conference presentation: MBX 6180. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $MGTX | MEIRAGTX HOLDINGS PLC | IND submission: native human leptin (Ribo-Leptin) · Metabolic disease. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-14; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $MGTX | MEIRAGTX HOLDINGS PLC | NDA/BLA submission: botaretigene sparoparvovec · RP X-linked retinitis pigmentosa. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $MIRM | Mirum Pharmaceuticals, Inc. | Brelovitug AZURE-4, the second pivotal chronic hepatitis delta study, topline expected in Q4 2026. 31 December is a conventional quarter-end marker; AZURE-1 results released on 28 September are a distinct study. | Estimated window | Primary source |
| Q4 2026 | $MIRM | Mirum Pharmaceuticals, Inc. | LIVMARLI EXPAND Phase 3 topline. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| By year-end 2026 | $MNKD | MANNKIND CORP | IND submission: Ralinepag DPI (MNKD-1501). Company timing: By year-end 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $NAMS | NEWAMSTERDAM PHARMA CO NV | Topline data: obicetrapib · T2D Type 2 diabetes or metabolic syndrome (Phase 3). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $NBTX | NANOBIOTIX SA | Full data: NBTXR3 · NSCLC (Phase 2). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-20; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $NKTR | NEKTAR THERAPEUTICS | Conference presentation: NKTR-0165 (preclinical). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $NRIX | NURIX THERAPEUTICS INC | Conference presentation: bexobrutideg · Relapsed or refractory B-cell malignancies (Phase 1a/1b). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-09; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2026 | $NRIX | NURIX THERAPEUTICS INC | IND submission: bexobrutideg · Autoimmune and inflammatory diseases (Phase 1). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-04-08; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 | $NUVB | NUVATION BIO INC | Preclinical drug-drug-conjugate platform update as Nuvation explores new candidates. No clinical patient-data release is specified. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $NVCR | NOVOCURE LTD | Regulatory decision: TTFields therapy · NSCLC Brain metastases from non-small cell lung cancer. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-23; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $OCUL | Ocular Therapeutix, Inc. | AXPAXLI wet AMD NDA submission with interim SOL-R safety analysis. ESTIMATED Q4 2026. Guidance reaffirmed after completed pre-NDA meeting. Submission is neither FDA acceptance nor approval. Primary issuer release syndicated on Nasdaq. | Estimated window | Primary source |
| Late 2026 | $OPK | OPKO HEALTH INC | IND submission: long-acting PTH tablet · Hypoparathyroidism. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-04-28; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ORIC | ORIC PHARMACEUTICALS INC | Initial data: enozertinib · NSCLC 1L EGFR exon 20 insertion NSCLC; NSCLC; Non-small cell lung cancer. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ORIC | ORIC PHARMACEUTICALS INC | Rinzimetostat program update. The source does not specify an interim clinical-data release. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ORKA | Oruka Therapeutics, Inc. | ORKA-004: planned entry into clinical development of the extended-half-life anti-TL1A antibody in Q4 2026. Phase 2 combination studies are a separate future milestone. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| Q4 2026 | $ORKA | Oruka Therapeutics, Inc. | EVERLAST-B ORKA-001 Week 16 data. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| December 2026 | $ORKA | Oruka Therapeutics, Inc. | EVERLAST-A ORKA-001 Week 52 data. ESTIMATED window: December 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Around mid-Q4 2026 | $OSTX | OS Therapies Incorporated | OST-HER2 confirmatory Phase 3 initiation. ESTIMATED window: around mid-Q4 2026. 2026-11-15 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q4 2026 | $PBLS | PARABILIS MEDICINES INC | FDA meeting: zolucatetide · Desmoid tumors (Phase 3). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $PCRX | PACIRA BIOSCIENCES INC | Topline data: ZILRETTA · Osteoarthritis pain of the shoulder (Phase 3). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-04-30; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $PCRX | PACIRA BIOSCIENCES INC | Topline data: enekinragene inzadenovec (PCRX-201) · Osteoarthritis of the knee (Phase 2). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $PCRX | PACIRA BIOSCIENCES INC | NDA/BLA submission: EXPAREL. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-26; checked 2026-10-04. | Estimated window | Primary source |
| By year-end 2026 | $PGEN | PRECIGEN INC | PRGN-2009 pipeline update in HPV-driven cancers; the quoted guidance does not specify a clinical-data release. Company timing: By year-end 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $PRAX | Praxis Precision Medicines | Relutrigine EMERALD Phase 3 topline in broad developmental and epileptic encephalopathies. ESTIMATED window: Q4 2026. Separate from the December 27 SCN2A/SCN8A PDUFA and registry completion dates. | Estimated window | Primary source |
| Q4 2026 | $PTCT | PTC THERAPEUTICS INC | Rolling NDA/BLA submission: ST-920 · Fabry disease (BLA-stage). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-21; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $PTCT | PTC THERAPEUTICS INC | FDA meeting: votoplam · HD Huntington's disease (Phase 3). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $PVLA | PALVELLA THERAPEUTICS INC | Rolling NDA/BLA submission: sirolimus (QTORIN rapamycin) · Microcystic lymphatic malformations (NDA). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $RAPP | RAPPORT THERAPEUTICS INC | Initial data: RAP-219 RAP-219. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $RARE | ULTRAGENYX PHARMACEUTICAL INC | Clinical data readout: rivunatpagene miziparvovec · Wilson disease Cyprus2+ (pivotal). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $RCUS | ARCUS BIOSCIENCES INC | Clinical data readout: casdatifan · ccRCC. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $REPL | REPLIMUNE GROUP INC | Full data: TUDRIQEV (vusolimogene oderparepvec-wtpg) · Skin cancers; CSCC ARTACUS (Phase 1b/2). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-14; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $REPL | REPLIMUNE GROUP INC | Initial data: RP2 (sturlimgene erparepvec) · HCC Hepatocellular carcinoma. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-14; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $RGNX | REGENXBIO Inc. | ATMOSPHERE and ASCENT pivotal surabgene lomparvovec topline in wet AMD. ESTIMATED Q4 2026. Distinct from registry primary-completion markers. December 31 is not an announced release day. | Estimated window | Primary source |
| Late 2026 | $RLAY | RELAY THERAPEUTICS INC | Zovegalisib: regulatory feedback to confirm the planned Phase 3 design in first-line endocrine-sensitive breast cancer, expected by year-end 2026. This is not a marketing-approval decision. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $RLAY | RELAY THERAPEUTICS INC | Zovegalisib: clinical data and regulatory update for the vascular-anomalies program, expected by year-end 2026. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $RXRX | RECURSION PHARMACEUTICALS INC | FDA meeting: REC-4881 · FAP. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $RXRX | RECURSION PHARMACEUTICALS INC | Interim data: REC-1245 (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $RZLT | Rezolute, Inc. | upLIFT ersodetug topline in tumor hyperinsulinism expected before end of 2026; enrollment ongoing. December 31 is a conventional window-end marker, not an announced release day. Separate from sunRIZE congenital HI and registry completion. | Estimated window | Primary source |
| 2026 | $SANA | Sana Biotechnology, Inc. | SC451 IND filing and Phase 1/2 trial start goal. ESTIMATED 2026. Company goal, conditional on nonclinical, manufacturing and regulatory execution. This event does not set a date for SG293 data. | Estimated window | Primary source |
| Q4 2026 | $SCYX | SCYNEXIS, Inc. | SCY-770 Phase 2 proof-of-concept initiation. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source Supporting source |
| Q4 2026 | $SLS | SELLAS LIFE SCIENCES GROUP INC | Topline data: tambiciclib · AML (Phase 2). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q4 2026 | $SNDX | Syndax Pharmaceuticals, Inc. | MAXPIRe axatilimab Phase 2 topline in idiopathic pulmonary fibrosis. ESTIMATED Q4 2026. December 31 is an indicative window-end marker, not a confirmed results date. | Estimated window | Primary source Supporting source |
| Late 2026 | $SNDX | SYNDAX PHARMACEUTICALS INC | IND submission: SNDX-4321 · NSCLC Non-small cell lung cancer. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $SNDX | SYNDAX PHARMACEUTICALS INC | Full data: Revuforj (revumenib) · NUP98r acute leukemia. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $SNDX | SYNDAX PHARMACEUTICALS INC | Conference presentation: Revuforj (revumenib). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $SNDX | Syndax Pharmaceuticals, Inc. | Axatilimab plus ruxolitinib Phase 2 topline in newly diagnosed chronic GVHD. ESTIMATED Q4 2026. December 31 is an indicative marker; distinct from Phase 3 corticosteroid combination. | Estimated window | Primary source Supporting source |
| H2 2026 | $SRPT | SAREPTA THERAPEUTICS INC | SRP-1001: further multiple-ascending-dose data from the ongoing Phase 1/2 trial in facioscapulohumeral muscular dystrophy (FSHD), expected in H2 2026. These are early clinical results, with no precise release day announced. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source Supporting source |
| H2 2026 | $SRPT | SAREPTA THERAPEUTICS INC | SRP-1003: further multiple-ascending-dose data from the ongoing Phase 1/2 trial in myotonic dystrophy type 1 (DM1), expected in H2 2026. These are early clinical results, with no precise release day announced. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source Supporting source |
| Late 2026 | $SRRK | SCHOLAR ROCK HOLDING CORP | Topline data: SRK-439 (Phase 1). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $STOK | STOKE THERAPEUTICS INC | FDA meeting: zorevunersen · DS Dravet syndrome (Phase 3). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $SYRE | SPYRE THERAPEUTICS INC | Topline data: SPY072 · PsA psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-25; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $TCRX | TScan Therapeutics, Inc. | ALLOHA Phase 1 Cohort C updated TSC-101 clinical data. ESTIMATED Q4 2026. Data guidance maintained despite a pause in further Phase 3 ALLOHA-2 enrollment; this is not Phase 3 topline. | Estimated window | Primary source |
| Q4 2026 | $TEVA | Teva Pharmaceutical Industries Limited | TEV-'749 olanzapine LAI PDUFA decision. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| H2 2026 | $TGTX | TG THERAPEUTICS INC | NDA/BLA submission: BRIUMVI (ublituximab-xiiy). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-27; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $TGTX | TG THERAPEUTICS INC | Initial data: azer-cel · Progressive MS (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $TNGX | TANGO THERAPEUTICS INC | Initial data: TNG456 · GBM Glioblastoma. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-06-08; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $TNGX | TANGO THERAPEUTICS INC | Vopimetostat monotherapy data in lung cancer. Separate from the pancreatic-cancer combination data scheduled for ESMO. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Topline data: ANB033 · Celiac disease (Phase 1b). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| By year-end 2026 | $TRDA | TRDA | ENTR-601-44: open-label follow-up from ELEVATE-44-201 Cohort 1 (6 mg/kg), assessing longer-term safety and functional measures in exon-44-skipping-amenable Duchenne muscular dystrophy, expected by year-end 2026. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| H2 2026 | $TRDA | TRDA | VX-670: partner Vertex expects multiple-ascending-dose results from GALILEO Phase 1/2 in myotonic dystrophy type 1 in H2 2026, covering safety, muscle-biopsy splicing and preliminary functional measures. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| Q4 2026 | $TRVI | TREVI THERAPEUTICS INC | LAKE Phase 2b refractory-chronic-cough study: sample-size re-estimation analysis after half the participants complete treatment. This is an operational interim analysis, not the final topline efficacy readout. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $TVTX | TRAVERE THERAPEUTICS INC | NDA/BLA submission: FILSPARI (sparsentan) · Japan. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-19; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $URGN | UROGEN PHARMA LTD | IND submission: UGN-501 · NMIBC High-grade non-muscle invasive bladder cancer. Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-02; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $VERA | Vera Therapeutics | TRUTAKNA full-approval sBLA submission planned Q4 2026. December 31 is a conventional end-of-window marker, not an exact company date or PDUFA. | Estimated window | Primary source |
| Q4 2026 | $VERA | VERA THERAPEUTICS INC | Additional Phase 2 PIONEER atacicept data in a broader IgA-nephropathy population and other autoimmune kidney diseases. Separate from the completed ORIGIN 3 eGFR analysis. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $VIR | VIR BIOTECHNOLOGY INC | Interim data: VIR-5818 · Solid tumors (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $VIR | VIR BIOTECHNOLOGY INC | Topline data: elebsiran and tobevibart · HDV Chronic hepatitis delta (Phase 3). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H2 2026 | $VRDN | VIRIDIAN THERAPEUTICS INC | Initial data: VRDN-008 (phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $VRDN | VIRIDIAN THERAPEUTICS INC | IND submission: anti-TSHR candidate · Graves' disease and TED. Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $VRDN | VIRIDIAN THERAPEUTICS INC | Development program update: VRDN-006. Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $XNCR | XENCOR INC | Conference presentation: XmAb541 (CLDN6 x CD3) · Advanced gynecologic and germ cell tumors (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-01-08; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $XNCR | XENCOR INC | Clinical program update: XmAb657 (CD19 x CD3) · Idiopathic inflammatory myopathies (Phase 1). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-25; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $XNCR | XENCOR INC | Interim data: XmAb942 (Xtend TL1A) · UC ulcerative colitis (UC) (Phase 2b). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $XNCR | XENCOR INC | NDA/BLA submission: obexelimab · Immunoglobulin G4-related disease. Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $XRTX | XORTX Therapeutics Inc. | XRx-026 gout IND submission. ESTIMATED window: Q4 2026. 2026-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| By year-end 2026 | $ZBIO | ZENAS BIOPHARMA INC | Initial data: ZB021 (Phase 1). Company timing: By year-end 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2026 | $ZBIO | ZENAS BIOPHARMA INC | Topline data: obexelimab · SLE Systemic lupus erythematosus (Phase 2). Company timing: Q4 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ZBIO | ZENAS BIOPHARMA INC | Marketing authorization application: obexelimab · Immunoglobulin G4-Related Disease (IgG4-RD). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 | $ZLAB | ZAI LAB LTD | IND submission: ZL-1311 (Phase 1). Company timing: Late 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ZLAB | ZAI LAB LTD | Initial data: ZL-1503 (IL-13/IL-31R) · AtD Atopic dermatitis (Phase 1/1b). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2026 | $ZYME | ZYMEWORKS INC | Conference presentation: pasritamig · Advanced prostate cancer (Phase 1b). Company timing: H2 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2026 | $ZYME | ZYMEWORKS INC | IND submission: ZW209 (Phase 1). Company timing: 2026. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| February 2027 | $ANAB | ANAPTYSBIO INC | PDUFA: Jemperli (dostarlimab) · Untreated stage II/III dMMR/MSI-H locally advanced rectal cancer AZUR-1 (pivotal). Company timing: February 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. FDA target action date; approval is not assured. Primary source dated 2026-09-21; checked 2026-10-04. | Estimated window | Primary source |
| February 2027 | $GSK | GSK / AnaptysBio | Jemperli rectal-cancer FDA action target communicated as February 2027 only; potential earlier review through National Priority Voucher. Exact day not disclosed. ESTIMATED window: February 2027. | Estimated window | Primary source |
| Early 2027 | $ACIU | AC Immune SA | FDA discussions on the future development path and Part 2 design of VacSYn, the Phase 2 trial of ACI-7104 in early Parkinson's disease. ESTIMATED window: early 2027. March 31 is a conventional end-of-window marker, not an announced meeting date. Not ACI-24.060 or ABATE. | Sources: ; | Checked: 2026-09-27 | Estimated window | Primary source Supporting source |
| Q1 2027 | $AEMD | Aethlon Medical, Inc. | NOR-101 Phase 1a start, proposed merger. ESTIMATED window: Q1 2027. 2027-03-31 is an indicative date within or at the end of that window, not a company-announced event day. Aethlon/North merger is proposed and conditional; NRTX is only a proposed future ticker. | Estimated window | Primary source |
| Q4 2026 or Q1 2027 | $ANAB | AnaptysBio / GSK | Jemperli litigation judgment anticipated Q4 2026 or Q1 2027; exact day unknown. | Estimated window | Primary source |
| Q1 2027 | $ATYR | aTyr Pharma, Inc. | EFZO-CONNECT efzofitimod Phase 2 topline in systemic sclerosis-related ILD. ESTIMATED Q1 2027. March 31 is an indicative marker. September 24 update addresses sarcoidosis protocol and does not replace this SSc-ILD readout guidance. | Estimated window | Primary source Supporting source |
| Q1 2027 | $BMEA | Biomea Fusion, Inc. | COVALENT-211 Phase 2 icovamenib Week 26 primary-endpoint topline in type 2 diabetes. ESTIMATED Q1 2027. Enrollment completed; company readout guidance separate from registry primary completion. | Estimated window | Primary source |
| Q1 2027 | $DYN | DYNE THERAPEUTICS INC | Topline data: zeleciment basivarsen (DYNE-101) · DM1 myotonic dystrophy type 1 (DM1) (Phase 1/2). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-29; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q1 2027 | $FLNA | Filana Therapeutics, Inc. | simufilam TSC epilepsy Phase 2a screening. ESTIMATED window: Q1 2027. 2027-03-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q1 2027 | $INBX | INHIBRX BIOSCIENCES INC | Interim data: ozekibart (INBRX-109) · CRC Colorectal cancer (Phase 1). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $IPHA | Innate Pharma S.A. | TELLOMAK-3 lacutamab first patient. ESTIMATED window: Q1 2027. 2027-03-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q1 2027 | $LGND | LIGAND PHARMACEUTICALS INC | Topline data: volixibat · PBC cholestatic pruritus due to primary biliary cholangitis (PBC) VANTAGE (Phase 2b). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $MIRA | MIRA Pharmaceuticals, Inc. | Ketamir-2 Phase 2a site initiation. ESTIMATED window: Q1 2027. 2027-03-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q1 2027 | $MIRM | MIRUM PHARMACEUTICALS INC | Topline data: volixibat · PBC Cholestatic pruritus due to primary biliary cholangitis VANTAGE (Phase 2b). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $NAMS | NEWAMSTERDAM PHARMA CO NV | Interim data: obicetrapib (Phase 3). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| early 2027 | $NKTR | Nektar Therapeutics | Planned registrational Phase 3 rezpegaldesleukin study initiation in alopecia areata. ESTIMATED early 2027. Early 2027 is company guidance; March 31 is only a conventional marker, not a promised deadline. | Estimated window | Primary source |
| Q1 2027 | $NKTR | NEKTAR THERAPEUTICS | Topline data: rezpegaldesleukin · AtD Moderate-to-severe atopic dermatitis. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-12; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $OCGN | Ocugen, Inc. | OCU400 Phase 3 liMeliGhT topline in retinitis pigmentosa. ESTIMATED Q1 2027. March 31 is an indicative window-end marker. The Bahamas provisional authorization is separate from FDA approval. | Estimated window | Primary source |
| Q1 2027 | $ORKA | ORUKA THERAPEUTICS INC | ORKA-002: Week 16 data from ORCA-SURGE, the Phase 2 trial in moderate-to-severe plaque psoriasis, expected in Q1 2027 after accelerated guidance. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $PALI | Palisade Bio, Inc. | ASCENTRA-CD Phase 2 Crohn's first patient. ESTIMATED window: Q1 2027. 2027-03-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q1 2027 | $PBLS | PARABILIS MEDICINES INC | Clinical data readout: zolucatetide · FAP. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $PHVS | PHARVARIS NV | CREAATE Phase 3 Part 1 topline results for deucrictibant XR prevention of attacks of acquired angioedema due to C1-inhibitor deficiency. This is not the CHAPTER-3 hereditary-angioedema trial. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q1 2027 | $REPL | REPLIMUNE GROUP INC | Planned transition of the REVEAL registration-directed RP2 study from Phase 2 to Phase 3 in metastatic uveal melanoma. This does not specify a public interim-data release. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-14; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $RNAC | Cartesian Therapeutics, Inc. | Descartes-08 AURORA Phase 3 generalized myasthenia gravis data expected Q1 2027 per company guidance. Distinct from the ClinicalTrials.gov primary-completion estimate; 31 March is a conventional quarter-end marker. | Estimated window | Primary source |
| Q1 2027 | $SEPN | SEPTERNA INC | Initial data: SEP-479 · Hypoparathyroidism (Phase 1). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $SRPT | SAREPTA THERAPEUTICS INC | ELEVIDYS: 12-week data from the full ENDEAVOR Cohort 8, expected in Q1 2027. Full cohort enrollment is separately expected by year-end 2026; no exact readout day is announced. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $STOK | STOKE THERAPEUTICS INC | Rolling NDA/BLA submission: zorevunersen · DS Dravet syndrome (Phase 3). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Year-end 2026 / Q1 2027 | $TGTX | TG THERAPEUTICS INC | Topline data: subcutaneous BRIUMVI (ublituximab) (Phase 3). Company timing: Year-end 2026 / Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Topline data: ANB033 · Celiac disease (Phase 1b). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $TRDA | TRDA | ENTR-601-44: ELEVATE-44-201 Cohort 2 multiple-ascending-dose data (12 mg/kg), expected in Q1 2027. Distinct from Cohort 1 open-label follow-up. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| Q1 2027 | $TYRA | TYRA BIOSCIENCES INC | Initial data: oral dabogratinib · Achondroplasia (Phase 2). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $VIR | VIR BIOTECHNOLOGY INC | Topline data: elebsiran and tobevibart · HDV Chronic hepatitis delta (Phase 3). Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q1 2027 | $VRDN | VIRIDIAN THERAPEUTICS INC | NDA/BLA submission: elegrobart · TED Thyroid eye disease. Company timing: Q1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2027 | $XENE | Xenon Pharmaceuticals Inc. | X-NOVA2 azetukalner Phase 3 MDD topline. ESTIMATED window: Q1 2027. 2027-03-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Mid-2027 | $CCCC | C4 Therapeutics, Inc. | Cemsidomide plus elranatamab Phase 1b data from all evaluated cohorts expected mid-2027. June 15 is a conventional marker for mid-year, not a company-announced day or precise quarter. Separate from Phase 1 dexamethasone data presented September 25, 2026. | Estimated window | Primary source |
| Early 2027 | $ABSI | ABSCI CORP | Topline data: ABS-201 · PHL; Pattern hair loss. Company timing: Early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $AZN | AstraZeneca PLC | efzimfotase alfa PDUFA action for hypophosphatasia. ESTIMATED window: H1 2027. 2027-06-30 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| H1 2027 | $BHC | BAUSCH HEALTH COMPANIES INC | Potential regulatory decision (company forecast): lumify (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-04-30; checked 2026-10-04. | Estimated window | Primary source |
| Q2 2027 | $BMEA | Biomea Fusion, Inc. | COVALENT-212 Phase 2 icovamenib Week 26 primary-endpoint topline on background GLP-1 therapy. ESTIMATED Q2 2027. Enrollment still ongoing in the source release; date remains guidance. | Estimated window | Primary source |
| H1 2027 | $CLYM | Climb Bio, Inc. | CLYM116 NAVIGATE-2 Phase 2 initial data in IgA nephropathy. ESTIMATED H1 2027. June 30 is a window-end marker; study evaluates Q8W/Q12W dosing. | Estimated window | Primary source |
| Late 2026 / early 2027 | $COAG | HEMAB THERAPEUTICS HOLDINGS INC | Clinical data readout: sutacimig · Factor VII deficiency (Phase 2). Company timing: Late 2026 / early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 / early 2027 | $COAG | HEMAB THERAPEUTICS HOLDINGS INC | Interim data: HMB-002 · Von Willebrand disease (Phase 1/2). Company timing: Late 2026 / early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H1 2027 | $CRMD | CorMedix Therapeutics | REZZAYO prophylaxis: potential FDA action subject to filing acceptance. ESTIMATED H1 2027. Conditional company guidance, not a confirmed PDUFA date. | Estimated window | Primary source |
| H1 2027 | $DFTX | Definium Therapeutics | DT120 ODT — NDA submission planned in 1H 2027. June 30 is a conventional end-of-window marker, not an exact submission date, PDUFA or approval. | Estimated window | Primary source |
| H1 2027 | $DNLI | DENALI THERAPEUTICS INC | Clinical data readout: DNL151 (LRRK2 inhibitor) · PD Parkinson's disease (Phase 2a). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $DNLI | DENALI THERAPEUTICS INC | Initial data: DNL628 · AD Alzheimer's disease (Phase 1b). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Early 2027 | $DRTS | ALPHA TAU MEDICAL LTD | Initial data: Alpha DaRT · PDAC pancreatic cancer IMPACT. Company timing: Early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-31; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Late 2026 / early 2027 | $DRTS | ALPHA TAU MEDICAL LTD | Topline data: Alpha DaRT · cutaneous squamous cell carcinoma ReSTART. Company timing: Late 2026 / early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H1 2027 | $ERAS | ERASCA INC | Interim data: ERAS-0015. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Q2 2027 | $ETON | ETON PHARMACEUTICALS INC | Regulatory decision: KHINDIVI (hydrocortisone). Company timing: Q2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-14; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $GPCR | STRUCTURE THERAPEUTICS INC | Topline data: ACCG-2671. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source Supporting source |
| Early 2027 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Topline data: BP-205 · Sleep-deprived healthy volunteers (Phase 1b). Company timing: Early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Topline data: EPX-100 (clemizole hydrochloride) · DS/LGS rare epilepsies; Dravet syndrome; Lennox-Gastaut syndrome (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Early 2027 | $HROW | HARROW INC | Topline data: TRIESENCE · ocular inflammation and pain following cataract surgery (Phase 3). Company timing: Early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $HROW | HARROW INC | Planned MELT-300 NDA submission following completion of the nonclinical and pharmacokinetic studies needed for the application. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-02; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 / early 2027 | $IDYA | IDEAYA BIOSCIENCES INC | Initial data: IDE034 (B7H3/PTK7 bispecific TOP1i ADC) (Phase 1). Company timing: Late 2026 / early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Early 2027 | $IMCR | IMMUNOCORE HOLDINGS PLC | Interim data: IMC-M113V (Phase 1/2). Company timing: Early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $IMTX | IMMATICS NV | Topline data: anzutresgene autoleucel (anzu-cel, IMA203) · Unresectable or metastatic melanoma (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-18; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $IOVA | IOVANCE BIOTHERAPEUTICS INC | Regulatory decision: Amtagvi (lifileucel) · melanoma. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $IOVA | IOVANCE BIOTHERAPEUTICS INC | Initial data: Amtagvi (lifileucel) · cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $IVA | Inventiva S.A. | Planned lanifibranor regulatory submission following NATiV3. ESTIMATED H1 2027. Conditional on favorable NATiV3 results; filing is not approval. | Estimated window | Primary source |
| H1 2027 | $JANX | Janux Therapeutics, Inc. | JANX007 additional clinical data at a future medical congress. ESTIMATED H1 2027. June 30 is an indicative marker. Congress and presentation day are not identified. | Estimated window | Primary source |
| H1 2027 | $KARD | KARDIGAN INC | Topline data: Tonlamarsen · Acute severe hypertension (Phase 2). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $KARD | KARDIGAN INC | Topline data: Danicamtiv · Genetic dilated cardiomyopathy (Phase 2b). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $KARD | KARDIGAN INC | Topline data: Ataciguat · Calcific aortic valve stenosis (Phase 2b). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Q2 2027 | $KOD | Kodiak Sciences | KSI-101 BLA submission planned. ESTIMATED window: Q2 2027. Company forward-looking plan dependent on development and regulatory execution; no exact filing day, acceptance, approval or PDUFA date announced. | Estimated window | Primary source |
| H1 2027 | $KRYS | KRYSTAL BIOTECH INC | Interim data: KB707 · Solid tumors of the lung (Phase 1/2). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H1 2027 | $LBRX | LB PHARMACEUTICALS INC | Topline data: LB-102 · SCZ Schizophrenia NOVA-2 (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-15; checked 2026-10-04. | Estimated window | Primary source |
| Q2 2027 | $LGND | LIGAND PHARMACEUTICALS INC | Topline data: avim therapy. Company timing: Q2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $MANE | VERADERMICS INC | Topline data: VDPHL01 · Female pattern hair loss (Phase 2/3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 / early 2027 | $MAZE | MAZE THERAPEUTICS INC | Interim data: MZE829 · broad AMKD patients; AMKD; APOL1-mediated kidney disease (Phase 2). Company timing: Late 2026 / early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-17; checked 2026-10-04. | Estimated window | Primary source |
| Q2 2027 | $MGTX | MEIRAGTX HOLDINGS PLC | Clinical data readout: AAV2-hAQP1 · Radiation-induced xerostomia (pivotal Phase 2). Company timing: Q2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H1 2027 | $MIRM | Mirum Pharmaceuticals, Inc. | Company expects to submit a brelovitug BLA for chronic hepatitis delta to FDA in H1 2027. This is a half-year window; 30 June is a conventional marker, not a filing confirmation. | Estimated window | Primary source |
| H1 2027 | $MIRM | MIRUM PHARMACEUTICALS INC | NDA/BLA submission: volixibat · PSC cholestatic pruritus due to PSC; Primary sclerosing cholangitis. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $MLTX | MoonLake Immunotherapeutics | IZAR-1 sonelokimab Phase 3 full Week 52 readout in psoriatic arthritis. ESTIMATED H1 2027. The trial remains blinded through Week 52. June 30 is a conventional window-end marker. | Estimated window | Primary source |
| Early 2027 | $NKTR | Nektar Therapeutics | ZENITH AA Phase 3 rezpegaldesleukin study in alopecia areata expected to initiate in early 2027. ESTIMATED window: early 2027; June 30 CSV date is only a conservative conventional window-end marker, not an announced start day. | Estimated window | Primary source |
| Q2 2027 | $OCGN | Ocugen, Inc. | OCU400 planned BLA submission for retinitis pigmentosa. ESTIMATED Q2 2027. June 30 is an indicative window-end marker; planned filing is not FDA acceptance or approval. | Estimated window | Primary source |
| H1 2027 | $OPK | OPKO HEALTH INC | Initial data: MDX2004 (Phase 1). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-27; checked 2026-10-04. | Estimated window | Primary source |
| Late 2026 / early 2027 | $OPK | OPKO HEALTH INC | Initial data: MDX2301 · COVID-19 Prevention of COVID-19 (Phase 1). Company timing: Late 2026 / early 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-27; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $PBLS | PARABILIS MEDICINES INC | Clinical data readout: zolucatetide · ACP. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $PCVX | VAXCYTE INC | Clinical data readout: VAX-31 · Invasive pneumococcal disease and pneumonia OPUS-2 OPUS-3 (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-03; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $PHVS | PHARVARIS NV | NDA/BLA submission: deucrictibant XR (PHVS719) · HAE CHAPTER-3 (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H1 2027 | $PVLA | PALVELLA THERAPEUTICS INC | Regulatory decision: sirolimus (QTORIN rapamycin) · Microcystic lymphatic malformations (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-20; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $QURE | UNIQURE NV | Conference presentation: AMT-260 · Refractory mesial temporal lobe epilepsy (Phase I/IIa). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-29; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $RARE | ULTRAGENYX PHARMACEUTICAL INC | Topline data: avalotcagene ontaparvovec · Ornithine Transcarbamylase deficiency Enh3ance (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $RCUS | ARCUS BIOSCIENCES INC | Clinical data readout: quemliclustat · PDAC Metastatic pancreatic ductal adenocarcinoma (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $RLAY | RELAY THERAPEUTICS INC | Zovegalisib plus atirmociclib and endocrine therapy: Phase 1/2 triplet clinical-data update in breast cancer, expected in H1 2027. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $RXRX | RECURSION PHARMACEUTICALS INC | Interim data: REC-3565 (Phase 1). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $RXRX | RECURSION PHARMACEUTICALS INC | Interim data: REC-617 (Phase 1). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $RXRX | RECURSION PHARMACEUTICALS INC | Initial data: REC-4881 · FAP; Familial adenomatous polyposis (Phase 1b/2). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-25; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $SCTX | Scribe Therapeutics Inc. | STX-1150 Phase 1 initial single-ascending-dose clinical data. ESTIMATED H1 2027. Planned data include safety, tolerability and LDL-C lowering. June 30 is a window-end marker. | Estimated window | Primary source |
| H1 2027 | $STOK | STOKE THERAPEUTICS INC | Initial data: STK-002 · ADOA; autosomal dominant optic atrophy ("ADOA") OSPREY (Phase 1). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $TARS | TARSUS PHARMACEUTICALS INC | TP-04 lotilaner ophthalmic-gel Phase 2 KORE topline results in ocular rosacea. TP-05/Calliope is a separate oral Lyme-disease prevention program. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Q2 2027 | $TCRX | TScan Therapeutics, Inc. | TSC-101 update on patients treated with the commercial-ready manufacturing process. ESTIMATED Q2 2027. Company continues patient follow-up despite enrollment pause; exact day not announced. | Estimated window | Primary source |
| H1 2027 | $TLX | TELIX PHARMACEUTICALS LTD | COMPOSE Phase 3 second interim analysis of ITM-11 in G2/G3 somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors. Telix announced an agreement to acquire ITM; closing remained subject to conditions in the September 21 source. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. ITM program; announced Telix acquisition pending closing. Primary source dated 2026-09-21; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| H1 2027 | $TRDA | TRDA | ENTR-601-45: ELEVATE-45-201 Cohort 2 multiple-ascending-dose data at 10 mg/kg, expected in H1 2027. Distinct from ELEVATE-44-201 Cohort 2. Exact event day is not announced. CSV Date is a conventional window-end marker. | Estimated window | Primary source |
| H1 2027 | $TSHA | TAYSHA GENE THERAPIES INC | Topline data: TSHA-102 · RTT Rett syndrome REVEAL (pivotal). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $VOR | VOR BIOPHARMA INC | Topline data: telitacicept · gMG Generalized myasthenia gravis (Phase 3). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $XNCR | XENCOR INC | Initial data: XmAb412 · Autoimmune and inflammatory disease. Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $ZLAB | ZAI LAB LTD | Initial data: ZL-1503 (IL-13/IL-31R) · AtD Atopic dermatitis (Phase 1/1b). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $ZLAB | ZAI LAB LTD | Topline data: ZL-6201 · sarcoma and selected tumors (Phase 1a/b). Company timing: H1 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H1 2027 | $ZNTL | Zentalis Pharmaceuticals, Inc. | DENALI Part 2 integrated azenosertib topline in Cyclin E1-positive platinum-resistant ovarian cancer. ESTIMATED H1 2027. June 30 is an indicative marker. Potential accelerated-approval support is conditional, not approval. | Estimated window | Primary source Supporting source |
| Mid-2027 | $AEMD | Aethlon Medical, Inc. | NOR-101 Phase 1a interim PK and safety data, proposed merger. ESTIMATED window: mid-2027. 2027-07-15 is an indicative date within or at the end of that window, not a company-announced event day. Aethlon/North merger is proposed and conditional; NRTX is only a proposed future ticker. | Estimated window | Primary source |
| Mid-2027 | $COAG | Hemab Therapeutics Holdings, Inc. | HMB-003 initial clinical data. ESTIMATED window: mid-2027. 2027-07-15 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Mid-2027 | $JAGX | Jaguar Health, Inc. | crofelemer MVID NDA filing. ESTIMATED window: mid-2027. 2027-07-15 is an indicative date within or at the end of that window, not a company-announced event day. Subject to study completion and regulatory alignment. | Estimated window | Primary source |
| Mid-2027 | $KYTX | Kyverna Therapeutics, Inc. | KYSA-6 Phase 3 miv-cel enrollment completion. ESTIMATED window: mid-2027. 2027-07-15 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q3 2027 | $ACAD | ACADIA PHARMACEUTICALS INC | Topline data: ACP-211 · MDD Major depressive disorder (Phase 2). Company timing: Q3 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-26; checked 2026-10-04. | Estimated window | Primary source |
| Q3 2027 | $BCRX | BIOCRYST PHARMACEUTICALS INC | Topline data: navenibart · HAE Hereditary angioedema (pivotal). Company timing: Q3 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Q3 2027 | $DYN | DYNE THERAPEUTICS INC | NDA/BLA submission: zeleciment basivarsen (DYNE-101) · DM1 myotonic dystrophy type 1 (DM1) (Phase 1/2). Company timing: Q3 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-29; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Q3 2027 | $STOK | STOKE THERAPEUTICS INC | Clinical data readout: zorevunersen · DS Dravet syndrome (Phase 3). Company timing: Q3 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Q3 2027 | $TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Topline data: ANB033 · EoE Eosinophilic esophagitis ANB033 (Phase 1b). Company timing: Q3 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $ABCL | ABCELLERA BIOLOGICS INC | IND submission: ABCL688 · Autoimmunity. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $ABSI | ABSCI CORP | Interim data: ABS-201 · Endometriosis HEADLINE (Phase 2). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $ABVX | ABIVAX SA | Topline data: obefazimod · CD Crohn's disease (Phase 2b). Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-21; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $ALKS | ALKERMES PLC | Clinical data readout: ALKS 7290 · ADHD attention-deficit hyperactivity disorder (ADHD) (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-21; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2027 | $ALMR | ALAMAR BIOSCIENCES INC | Device marketing authorization submission: ARGO HT/DX instrument. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $ALT | Altimmune, Inc. | RESTORE Phase 2 pemvidutide topline in alcohol-associated liver disease. ESTIMATED H2 2027. Enrollment completed in July 2026. Topline concerns updated 48-week endpoint, not enrollment. Window-end marker is not an announced release day. | Estimated window | Primary source |
| 2027 | $AMLX | AMYLYX PHARMACEUTICALS INC | IND submission: AMX0318 · PBH and other rare diseases. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $AVLN | AVALYN PHARMA INC | Topline data: ap01 (inhaled pirfenidone) · Progressive pulmonary fibrosis (Phase 2b). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 | $AVLN | AVALYN PHARMA INC | Topline data: ap02 (inhaled nintedanib) · IPF Idiopathic pulmonary fibrosis (Phase 2). Company timing: Late 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $AXSM | AXSOME THERAPEUTICS INC | Topline data: solriamfetol · Shift work disorder SUSTAIN (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $BCAX | BICARA THERAPEUTICS INC | Interim data: ficerafusp alfa · 1L R/M HPV-negative HNSCC FORTIFI-HN01 (Phase 3). Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 | $BCRX | BIOCRYST PHARMACEUTICALS INC | NDA/BLA submission: navenibart. Company timing: Late 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $BIOA | BioAge Labs, Inc. | QUELL-DME BGE-102 Phase 2 topline in diabetic macular edema. ESTIMATED H2 2027. December 31 is an indicative marker. Primary endpoint is BCVA change at week 12. | Estimated window | Primary source |
| H2 2027 | $BRVE | BRAVEHEART BIO INC | Interim data: BHB-1893 · obstructive HCM ("oHCM") (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $CLDX | Celldex Therapeutics, Inc. | barzolvolimab CSU BLA submission. ESTIMATED window: 2027. 2027-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| 2027 | $CNMD | CONMED CORP | Clinical data readout: BioBrace · rotator cuff. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-01-12; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $DFTX | DEFINIUM THERAPEUTICS INC | Topline data: DT120 ODT · MDD Major depressive disorder (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $DMRA | DAMORA THERAPEUTICS INC | Initial data: DMR-001 · Essential thrombocythemia and myelofibrosis; ET and MF. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $DMRA | DAMORA THERAPEUTICS INC | IND submission: DMR-003. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-10; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $DNLI | DENALI THERAPEUTICS INC | Initial data: DNL952 · Pompe disease (Phase 1). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $DNLI | DENALI THERAPEUTICS INC | Clinical data readout: DNL921 · AD Alzheimer's disease (Phase 1/1b). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $DNLI | DENALI THERAPEUTICS INC | Clinical data readout: DNL593 · granulin ( GRN )-related frontotemporal dementia (FTD- GRN ) (Phase 1/2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $DNLI | DENALI THERAPEUTICS INC | NDA/BLA submission: zafinofusp alfa (DNL126; ETV:SGSH) · Sanfilippo syndrome type A (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| By year-end 2027 | $DNTH | DIANTHUS THERAPEUTICS INC | DNTH312 development target is Phase 1 readiness by year-end 2027. The quoted statement does not establish an IND filing date or first-patient dosing date. Company timing: By year-end 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $ETON | ETON PHARMACEUTICALS INC | NDA/BLA submission: ASN-001 · Moderate infantile hemangiomas. Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2027 | $HCM | HUTCHMED (CHINA) LTD | Topline data: IMG-007 · AtD moderate-to-severe atopic dermatitis (Phase IIb). Company timing: Q4 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2027 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Topline data: Pitolisant HD · Narcolepsy; Idiopathic hypersomnia; Narcolepsy (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Pitolisant (WAKIX): topline data from the Phase 3 TEMPO study in Prader-Willi syndrome are expected around mid-2027. This is distinct from pitolisant GR in narcolepsy. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $IDYA | IDEAYA BIOSCIENCES INC | Interim data: darovasertib combination · Metastatic uveal melanoma. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $IMCR | IMMUNOCORE HOLDINGS PLC | Initial data: IMC-R117C · CRC advanced solid tumors, including colorectal cancer (Phase 1/2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $IMTX | IMMATICS NV | IMA401 (MAGEA4/8) plus IMA402 (PRAME): first clinical data from the combination cohort in squamous non-small-cell lung cancer expected in 2027. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-18; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2027 | $IMTX | IMMATICS NV | Anzu-cel BLA submission planned in 2027 after final SUPRAME progression-free-survival topline data expected in the first half of 2027. The newer August guidance no longer specifies a first-half filing deadline. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-18; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $IMVT | IMMUNOVANT INC | Topline data: imeroprubart (IMVT-1402) · Graves' disease (potentially registrational). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2027 | $IMVT | IMMUNOVANT INC | Topline data: imeroprubart (IMVT-1402) · gMG Myasthenia gravis (potentially registrational). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Mid-2027 (approximate) | $INBX | INHIBRX BIOSCIENCES INC | Initial data: INBRX-106 · NSCLC Non-small cell lung cancer (Phase 1/2). Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $IONS | IONIS PHARMACEUTICALS INC | Clinical data readout: obudanersen · Angelman syndrome REVEAL (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-29; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $IONS | IONIS PHARMACEUTICALS INC | NDA/BLA submission: ZANVASTRO (zilganersen). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-04; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $IOVA | IOVANCE BIOTHERAPEUTICS INC | Marketing authorization resubmission: Amtagvi (lifileucel) · Advanced melanoma. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $IRON | DISC MEDICINE INC | Regulatory decision: bitopertin · EPP. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $IRON | DISC MEDICINE INC | Initial data: selcodebart (DISC-0974) · IBD Inflammatory bowel disease (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $KLRA | KAILERA THERAPEUTICS INC | Clinical data readout: HRS-7535 (KAI-7535) · Obesity (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $KLRA | KAILERA THERAPEUTICS INC | Clinical data readout: HRS-4729 (KAI-4729) (Phase 1). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $KLRA | KAILERA THERAPEUTICS INC | Ribupatide injection: Phase 2b high-dose obesity data in 264 participants with BMI at least 35 and no type 2 diabetes. The 48-week trial evaluates 10, 13, 16 and 20 mg weekly doses; data anticipated around mid-2027. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source Supporting source |
| 2027 | $KRYS | KRYSTAL BIOTECH INC | Interim data: KB408 · AATD Alpha-1 Antitrypsin Deficiency Lung Disease (Phase 1). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2027 | $KYMR | KYMERA THERAPEUTICS INC | IND submission: KT-200 · breast cancer and other solid tumors. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 | $KYMR | KYMERA THERAPEUTICS INC | Clinical data readout: KT-621 · Asthma (Phase 2b). Company timing: Late 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $LBRX | LB PHARMACEUTICALS INC | FDA meeting: LB-102 · SCZ Schizophrenia (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $LGND | LIGAND PHARMACEUTICALS INC | Topline data: lasofoxifene · Metastatic breast cancer ELAINE-3 (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $LGND | LIGAND PHARMACEUTICALS INC | Topline data: Qtorin 3.9% rapamycin anhydrous gel (Qtorin rapamycin) · Angiokeratomas (Phase 2). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-07; checked 2026-10-04. | Estimated window | Primary source |
| Q4 2027 | $LSTA | Lisata Therapeutics, Inc. | MAR002 acromegaly Phase 2 topline. ESTIMATED window: Q4 2027. 2027-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| Q4 2027 | $LSTA | Lisata Therapeutics, Inc. | MAR001 severe hypertriglyceridemia Phase 2b topline. ESTIMATED window: Q4 2027. 2027-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| H2 2027 | $LTGO | Latigo Biotherapeutics, Inc. | LTG-321 Phase 2 topline in osteoarthritis knee pain. ESTIMATED H2 2027. December 31 is an indicative window-end marker. | Estimated window | Primary source |
| H2 2027 | $LTGO | Latigo Biotherapeutics, Inc. | Onzotrigine Phase 3 bunionectomy and open-label safety topline. ESTIMATED H2 2027. December 31 is an indicative window-end marker; exact day not announced. | Estimated window | Primary source |
| H2 2027 | $LXEO | Lexeo Therapeutics, Inc. | SUNRISE-FA 2 LX2006 topline. ESTIMATED window: H2 2027. 2027-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| 2027 | $MAZE | MAZE THERAPEUTICS INC | Topline data: MZE782 · PKU PKU; Phenylketonuria (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $MBX | MBX BIOSCIENCES INC | MBX 4291: topline results from the Phase 1 obesity study are anticipated in 2027. The program studies single and multiple ascending doses of a GLP-1/GIP co-agonist prodrug; this overall readout is distinct from the first 12-week cohort update in Q4 2026. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-12; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| Mid-2027 (approximate) | $MESO | MESOBLAST LTD | Topline data: rexlemestrocel-l · chronic low back pain (CLBP) (Phase 3). Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-27; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $MESO | MESOBLAST LTD | NDA/BLA submission: rexlemestrocel-l · Chronic low back pain (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-04-29; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $MGTX | MEIRAGTX HOLDINGS PLC | NDA/BLA submission: AAV2-hAQP1 · Radiation-induced xerostomia (pivotal). Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $MIRM | MIRUM PHARMACEUTICALS INC | Topline data: MRM-3379 · Fragile X syndrome BLOOM (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $MIRM | MIRUM PHARMACEUTICALS INC | Topline data: brelovitug · HDV Chronic hepatitis delta virus infection AZURE-2 AZURE-3 (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-28; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $MIRM | MIRUM PHARMACEUTICALS INC | Potential US regulatory approval of brelovitug after the planned H1 2027 BLA submission, subject to FDA review. The September 28 update targets a potential US commercial launch in Q4 2027 if approved. Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-28; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 | $MNKD | MANNKIND CORP | Clinical data readout: insulin human (Afrezza) · T1D newly-diagnosed type 1 diabetes. Company timing: Late 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-28; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $NKTR | NEKTAR THERAPEUTICS | Initial data: rezpegaldesleukin · T1D Type 1 diabetes mellitus (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $NUVB | NUVATION BIO INC | Clinical data readout: safusidenib · grade 3 IDH1 -mutant oligodendroglioma. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-04; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $OGN | ORGANON & CO | Regulatory decision: Nexplanon. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-31; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $PCVX | VAXCYTE INC | Topline data: VAX-A1 · Disease caused by Group A Streptococcus (Phase 1). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $PODD | INSULET CORP | 510(k) submission: fully closed-loop automated insulin delivery (AID) system · T2D Type 2 diabetes EVOLVE (pivotal). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $PRAX | PRAXIS PRECISION MEDICINES INC | Topline data: elsunersen · SCN2A DEE EMBRAVE3. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $PRAX | PRAXIS PRECISION MEDICINES INC | NDA/BLA submission: vormatrigine · FOS POWER1 POWER2 (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-19; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $PRAX | PRAXIS PRECISION MEDICINES INC | NDA/BLA submission: relutrigine · SCN2A and SCN8A DEEs EMERALD. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-19; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $PRAX | PRAXIS PRECISION MEDICINES INC | Topline data: vormatrigine · FOS (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-19; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $PVLA | PALVELLA THERAPEUTICS INC | Topline data: sirolimus (QTORIN rapamycin) · Clinically significant angiokeratomas LOTU (Phase 2). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $RAPP | RAPPORT THERAPEUTICS INC | Initial data: RAP-219. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $RCUS | ARCUS BIOSCIENCES INC | AB102 proof-of-concept study milestone in chronic spontaneous urticaria. The quoted source forecasts the study, not a dated release of initial results. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $REPL | REPLIMUNE GROUP INC | RP1 (vusolimogene oderparepvec) plus nivolumab: interim overall-survival analysis from the randomized Phase 3 IGNYTE-3 trial in advanced melanoma is planned for H2 2027. This is distinct from the primary overall-survival readout expected in 2030; no exact day is announced. Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-03; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $RXRX | RECURSION PHARMACEUTICALS INC | Interim data: REC-4539 (Phase 1). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $SABS | SAB Biotherapeutics, Inc. | SAFEGUARD SAB-142 Phase 2b topline. ESTIMATED window: H2 2027. 2027-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source |
| H2 2027 | $SCYX | SCYNEXIS, Inc. | SCY-770 Phase 2 early efficacy data. ESTIMATED window: H2 2027. 2027-12-31 is an indicative date within or at the end of that window, not a company-announced event day. | Estimated window | Primary source Supporting source |
| 2027 | $SNDX | SYNDAX PHARMACEUTICALS INC | IND submission: SNDX-62122 · Myelofibrosis. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $SNDX | SYNDAX PHARMACEUTICALS INC | Initial data: Revuforj (revumenib) · Myelofibrosis; MF (Phase 1/2). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 | $STOK | STOKE THERAPEUTICS INC | Conditional US commercial launch target for zorevunersen, dependent on regulatory submission and approval. It is not an NDA filing deadline. Company timing: Late 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $SUPN | SUPERNUS PHARMACEUTICALS INC | Potential FDA authorization of a second supplier for ONAPGO. This concerns manufacturing supply for an already approved treatment, not initial marketing approval. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $SYRE | SPYRE THERAPEUTICS INC | Topline data: SPY001, SPY002, SPY003, SPY120, SPY130, SPY230 · UC Ulcerative colitis (Phase 2). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $TARS | TARSUS PHARMACEUTICALS INC | Regulatory decision: XDEMVY (lotilaner ophthalmic solution) · Demodex blepharitis. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-23; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $TRVI | TREVI THERAPEUTICS INC | Topline data: Haduvio (oral nalbuphine ER) · IPF Idiopathic pulmonary fibrosis-related chronic cough OCEAN-2 (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $TRVI | TREVI THERAPEUTICS INC | Topline data: Haduvio (oral nalbuphine ER) · Refractory chronic cough; IPF-related chronic cough; non-IPF ILD-related chronic cough (Phase 2b). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $TVTX | TRAVERE THERAPEUTICS INC | Conference presentation: FILSPARI (sparsentan) · recurrent IgAN or FSGS. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $TVTX | TRAVERE THERAPEUTICS INC | Topline data: pegtibatinase · classical Homocystinuria (HCU) (Phase 3). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $TYRA | TYRA BIOSCIENCES INC | Initial data: oral dabogratinib · FGFR3-altered LG-UTUC; Low-grade upper tract urothelial carcinoma (Phase 2a/b). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $URGN | UROGEN PHARMA LTD | Regulatory decision: UGN-103 · NMIBC Recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-02; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2027 (approximate) | $VCRE | VICORE PHARMA HOLDING AB | Topline data: buloxibutid · IPF. Company timing: Mid-2027 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-21; checked 2026-10-04. | Estimated window | Primary source Supporting source |
| 2027 | $VERA | VERA THERAPEUTICS INC | Regulatory decision: atacicept · IgAN IgA nephropathy (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-15; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $XENE | XENON PHARMACEUTICALS INC | Initial data: NBI-921355 · Certain types of epilepsy (Phase 1). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-07; checked 2026-10-04. | Estimated window | Primary source |
| H2 2027 | $XNCR | XENCOR INC | Topline data: XmAb942 (Xtend TL1A) · UC Ulcerative colitis (Phase 2b). Company timing: H2 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $XNCR | XENCOR INC | Phase 1 combination dose escalation of XmAb541 and XmAb808 is expected to reach its target dose range in 2027. No dated interim-data disclosure is specified. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-05; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $ZBIO | ZENAS BIOPHARMA INC | ZB022: Phase 1 initiation for the oral, brain-penetrant TYK2-JH2 inhibitor is expected in 2027, subject to IND-enabling study results and regulatory clearance. This replaces the earlier 2026 plan. Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $ZLAB | ZAI LAB LTD | Topline data: elegrobart · TED Thyroid eye disease (Phase 3). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $ZLAB | ZAI LAB LTD | IND submission: ZL-1222 (PD-1 / IL-12) (Phase 1). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2027 | $ZYME | ZYMEWORKS INC | IND submission: ZW1528 · COPD Chronic obstructive pulmonary disease (Phase 1). Company timing: 2027. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Approximately November 2027-January 2028 (18-20 months from May 11, 2026) | $HROW | HARROW INC | FDA filing planned for the TRIESENCE prefilled-syringe format within 18-20 months of the May 11, 2026 update. This corresponds approximately to November 2027-January 2028 and is separate from the cataract-surgery/pain clinical study. Company timing: Approximately November 2027-January 2028 (18-20 months from May 11, 2026). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-11; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2028 | $LBRX | LB PHARMACEUTICALS INC | Topline data: LB-102 · Bipolar depression ILLUMINATE-1 (Phase 2). Company timing: Q1 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| Q1 2028 | $OCUL | OCULAR THERAPEUTIX INC | Topline data: AXPAXLI · nAMD wet AMD SOL-R (Phase 3). Company timing: Q1 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-03; checked 2026-10-04. | Estimated window | Primary source |
| Early 2028 | $PALI | Palisade Bio, Inc. | ASCENTRA-CD Crohn's Phase 2 primary efficacy readout. ESTIMATED window: early 2028. 2028-03-31 is an indicative date within or at the end of that window, not a company-announced event day. Early 2028 is represented operationally as January-March, not an announced exact quarter. | Estimated window | Primary source |
| H1 2028 | $HROW | HARROW INC | G-MELT: potential FDA approval in H1 2028 under the company development plan, following the intended H1 2027 NDA submission. This is a conditional forecast, not an assigned PDUFA deadline; potential launch is a separate H2 2028 milestone. Company timing: H1 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-06; checked 2026-10-04. | Estimated window | Primary source |
| Early 2028 | $SNDX | SYNDAX PHARMACEUTICALS INC | Topline data: axatilimab · GVHD Chronic graft-versus-host disease (Phase 3). Company timing: Early 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 / early 2028 | $SYRE | SPYRE THERAPEUTICS INC | Clinical data readout: SPY072 + IL-17A/F · HS. Company timing: Late 2027 / early 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source |
| H1 2028 | $TRVI | TREVI THERAPEUTICS INC | Topline data: Haduvio (oral nalbuphine ER) · IPF Idiopathic pulmonary fibrosis-related chronic cough OCEAN-1 (Phase 3). Company timing: H1 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Late 2027 / early 2028 | $ZYME | ZYMEWORKS INC | Topline data: EmpowHER-303 HER-303. Company timing: Late 2027 / early 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $ANAB | ANAPTYSBIO INC | Topline data: Jemperli (dostarlimab) · CRC Colorectal cancer and dMMR pan tumors (Phase 3). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-03-03; checked 2026-10-04. | Estimated window | Primary source |
| Late 2028 | $CELC | CELCUITY INC | Topline data: REVTORPYK (gedatolisib) · endocrine-resistant HR+/HER2- ABC (Phase 3). Company timing: Late 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| H2 2028 | $DNTH | DIANTHUS THERAPEUTICS INC | Topline data: claseprubart · gMG Generalized myasthenia gravis EMERGE (Phase 3). Company timing: H2 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2028 | $GPCR | STRUCTURE THERAPEUTICS INC | Topline data: aleniglipron · Chronic weight management ACCOMPLISH-1 ACCOMPLISH-2 (Phase 3). Company timing: H2 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-08; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $HCM | HUTCHMED (CHINA) LTD | Initial data: IMG-007 · Alopecia areata (Phase II). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-07-30; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Potential regulatory decision (company forecast): WAKIX (pitolisant) (Phase 3). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Potential regulatory decision (company forecast): Pitolisant HD · Narcolepsy. Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Potential regulatory decision (company forecast): EPX-100 (clemizole hydrochloride) · DS Dravet Syndrome and Lennox-Gastaut Syndrome; rare epilepsies (Phase 3). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-04; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $IMVT | IMMUNOVANT INC | Topline data: imeroprubart (IMVT-1402) · Sjögren's disease (potentially registrational). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2028 | $IMVT | IMMUNOVANT INC | Topline data: imeroprubart (IMVT-1402) · CIDP Chronic inflammatory demyelinating polyneuropathy (potentially registrational). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source Trial registry |
| 2028 | $KLRA | KAILERA THERAPEUTICS INC | Clinical data readout: ribupatide injection (KAI-9531) · Obesity (Phase 3). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-12; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $LGND | LIGAND PHARMACEUTICALS INC | Clinical data readout: Qarziba · Neuroblastoma BEACON-2. Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-02-27; checked 2026-10-04. | Estimated window | Primary source |
| Mid-2028 (approximate) | $NKTR | NEKTAR THERAPEUTICS | Clinical data readout: rezpegaldesleukin (Phase 3). Company timing: Mid-2028 (approximate). Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| 2028 | $TARS | TARSUS PHARMACEUTICALS INC | Topline data: aqueous chlorine dioxide solution (IRX-101) COMFORT (Phase 3). Company timing: 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| Late 2028 | $XERS | XERIS BIOPHARMA HOLDINGS INC | XP-8121: topline results from the Cornerstone Phase 3 program in hypothyroidism are forecast for late 2028. This is a company development projection. Company timing: Late 2028. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-09; checked 2026-10-04. | Estimated window | Primary source |
| Early 2029 | $ATAI | ATAIBECKLEY INC | Topline data: BPL-003 (Phase 3). Company timing: Early 2029. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-12; checked 2026-10-04. | Estimated window | Primary source |
| H1 2029 | $LBRX | LB PHARMACEUTICALS INC | Topline data: LB-102 · adjunctive treatment of MDD (Phase 2). Company timing: H1 2029. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-11; checked 2026-10-04. | Estimated window | Primary source |
| 2029 | $NKTR | NEKTAR THERAPEUTICS | Target for the first rezpegaldesleukin BLA submission. This is company development guidance, not a scheduled FDA approval decision. Company timing: 2029. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| 2029 | $NUVB | NUVATION BIO INC | Clinical data readout: safusidenib · IDH1 -mutant astrocytoma (pivotal Phase 3). Company timing: 2029. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-05-04; checked 2026-10-04. | Estimated window | Primary source |
| H2 2029 | $TARS | TARSUS PHARMACEUTICALS INC | Topline data: gildeuretinol (ALK-001) · Stargardt disease (Phase 3). Company timing: H2 2029. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-06; checked 2026-10-04. | Estimated window | Primary source |
| 2030 | $CELC | CELCUITY INC | Topline data: REVTORPYK (gedatolisib) · endocrine-sensitive HR+/HER2- ABC (Phase 3). Company timing: 2030. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-13; checked 2026-10-04. | Estimated window | Primary source |
| 2030 | $REPL | REPLIMUNE GROUP INC | RP1 (vusolimogene oderparepvec) plus nivolumab: primary overall-survival readout from Phase 3 IGNYTE-3 is expected in 2030. The trial compares the combination with physician's choice in advanced melanoma after anti-PD-1 and anti-CTLA-4 therapies or when anti-CTLA-4 is unsuitable. The H2 2027 interim OS analysis is a separate milestone. Company timing: 2030. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-08-14; checked 2026-10-04. | Estimated window | Primary source |
| 2030 | $XERS | XERIS BIOPHARMA HOLDINGS INC | XP-8121: potential FDA approval and commercial launch in 2030 are long-range company projections, conditional on trial outcomes and regulatory review; no assigned PDUFA date. Company timing: 2030. Exact event day is not announced. CSV Date is a conventional window-end marker, not an announced event day. Primary source dated 2026-09-09; checked 2026-10-04. | Estimated window | Primary source Supporting source |
The following rows record completed events and dates that have passed. A past date does not prove an outcome or that a scheduled presentation occurred; uncertain status is stated in each row.
| Date / window | Ticker | Company | Event | Status | Sources |
|---|---|---|---|---|---|
| Aug 12, 2026 — announcement | $ALT | Altimmune, Inc. | RESTORE Phase 2 enrollment completed in July 2026; announcement August 12Exact July completion day not disclosed. This row uses the announcement date; the H2 2027 topline is a separate future milestone. | HISTORICAL · Completed event | Primary source |
| Sep 21, 2026 | $NAMS | NewAmsterdam Pharma | Ubeslo / Evlarco: European Commission authorizationEU authorization announced September 21; the former September 28 estimated marker is resolved. | HISTORICAL · Completed event | Primary source |
| $GRAL | GRAIL | Galleri — multi-cancer early detection test for adults aged 50 and overOn September 23, the advisory panel voted 7–2 with one abstention that benefits outweigh risks; safety 10–0; effectiveness 6–4, according to GRAIL. The vote is nonbinding. FDA review of the Galleri PMA continues; this is not approval. | HISTORICAL · FAVORABLE ADCOM — FDA PENDING | GRAIL · FDA | |
| Sep 23, 2026 | $ARCT | Arcturus Therapeutics | ARCT-810 Phase 2 interim results and LUNAR 2.0 update releasedSeptember 23 release and webcast resolve the former September 30 estimated marker. ARCT-2601 integration is a separate future milestone. | HISTORICAL · Completed event | Primary source |
| 2026-09-24 | $MRK | Merck & Co. | Belzutifan plus lenvatinib FDA-approved September 24; former October 4 target resolved. | HISTORICAL · FDA approved | Primary source |
| $MIRM | Mirum Pharmaceuticals | Atebrioz (zilurgisertib)FDA lists approval on September 25, 2026 for reducing new heterotopic ossification in adults and patients aged 12 and older with FOP. Former September 26 PDUFA target resolved; licensed from Incyte. | HISTORICAL · FDA APPROVED | FDA | |
| 2026-09-25 | $MRK | Merck & Co. | Ifinatamab deruxtecan BLA voluntarily withdrawn September 25; former October 10 target superseded. Phase 3 continues. | HISTORICAL · Application withdrawn | Primary source |
| 2026-09-28 | $KOD | Kodiak Sciences | DAYBREAK: Zenkuda and KSI-501 met vision non-inferiority primary endpoints versus aflibercept; sponsor topline September 28. Zenkuda 54% at 24-week dosing. Not FDA approval. | HISTORICAL · Results published | Primary source |
| Sep 24, 2026 | $KYTX | Kyverna Therapeutics, Inc. | Phase 2 longer-term miv-cel follow-up in generalized myasthenia gravis released September 24, 2026. The former Q3 window is resolved. | HISTORICAL · Results released | Primary source |
| Sep 24, 2026 | $KYTX | Kyverna Therapeutics, Inc. | One-year miv-cel topline in stiff person syndrome released September 24, 2026. The former Q3 window is resolved. | HISTORICAL · Results released | Primary source |
| Sep 24, 2026 | $ACAD | Acadia Pharmaceuticals Inc. | Phase 2 remlifanserin topline released September 24, 2026. Primary endpoint missed statistical significance (p=0.0603); Phase 3 continuation planned with protocol amendments. | HISTORICAL · Results released | Primary source |
| 2026-09-28 | $ACET | Adicet Bio, Inc. | Prula-cel Phase 1 clinical data released in SLE/LN. | HISTORICAL — Results released | Primary source |
| 2026-09-28 | $MIRM | Mirum Pharmaceuticals | AZURE-1 Phase 3 brelovitug topline released; primary endpoint met. | HISTORICAL — Results released | Primary source |
| 2026-09-29 | $IVVD | Invivyd, Inc. | LIBERTY Phase 3 VYD2311 safety/tolerability topline released; distinct DECLARATION study remains pending. | HISTORICAL — Results released | Primary source |
| Q3 2026 | $IVVD | Invivyd, Inc. | Prior combined LIBERTY/DECLARATION forecast superseded by separate company updates on 29 September. | HISTORICAL — Superseded forecast | Primary source |
| 2026-09-28 | $IVA | Inventiva S.A. | First-half 2026 financial results published; 08:00 ET call announced, occurrence not separately verified. | HISTORICAL — Results released | Primary source |
| 2026-09-28 | $IMMP | Immutep Limited | Announced ADS-ratio change; market execution not independently verified. | HISTORICAL — Execution unverified | Primary source |
| 2026-09-28 | $SABS | SAB Biotherapeutics | SAB-142 Phase 1 presentation scheduled at EASD; occurrence not independently verified. | HISTORICAL — Occurrence unverified | Primary source |
| 2026-09-29 | $KYTX | Kyverna Therapeutics | KYSA-6 Phase 2 follow-up presentation scheduled at AANEM; occurrence not independently verified. | HISTORICAL — Occurrence unverified | Primary source |
| $SRPT | Sarepta Therapeutics | WMS Duchenne data presentationsScheduled scientific presentation, not an automatic pivotal readout. Stock Hub | HISTORICAL — Occurrence unverified | Primary source | |
| Sep 30, 2026 | $INCY | Incyte Corporation | STOP-HS Phase 3 povorcitinib posters at EADV 2026. Incyte lists two povorcitinib STOP-HS1/STOP-HS2 Phase 3 poster abstracts for the EADV 2026 session on 30 September 2026 at 07:00 CEST, covering acne and high-disease-burden analyses. This is a congress presentation of additional analyses, not a new topline readout | HISTORICAL — Occurrence unverified | Primary source |
| Sep 30, 2026 | $INCY | Incyte Corporation | TRuE-AD4 ruxolitinib cream poster at EADV 2026. Incyte lists the TRuE-AD4 poster on ruxolitinib cream in moderate atopic dermatitis for the EADV 2026 session on 30 September 2026 at 07:00 CEST. This is a congress presentation, not a new pivotal topline readout | HISTORICAL — Occurrence unverified | Primary source |
| Sep 30, 2026 | $SABS | SAB Biotherapeutics, Inc. | three SAB-142 Phase 1 presentations at EASD 2026 | HISTORICAL — Occurrence unverified | Primary source |
| Oct 1, 2026 · 16:30 CEST | $NKTR | Nektar Therapeutics | REZOLVE-AA Phase 2b 52-week rezpegaldesleukin data oral presentation at EADVPresentation 16:30-16:40 CEST, Hall N, abstract AS-1872; conference discussion of previously reported data. | HISTORICAL — Results released | Primary source |
| Oct 1, 2026 · 10:25 CEST | $NKTR | Nektar Therapeutics | REZOLVE-AD Phase 2b maintenance rezpegaldesleukin data oral presentation at EADVPresentation 10:25-10:35 CEST, Hall N, abstract AS-1732; distinct from initial topline. | HISTORICAL — Results released | Primary source |
| Oct 1, 2026 · session 16:30–18:00 CEST | $ARTV | Artiva Biotherapeutics, Inc. | AlloNK (AB-101) plus rituximab Sjogren disease clinical data presentation at ISSjDConfirmed presentation day. Session 16:30-18:00 CEST; individual talk time unspecified. Data from 11 patients; not a Phase 3 RA readout. | HISTORICAL — Results released; oral session unverified | Primary source |
| Oct 1, 2026 · 16:30 CEST | $EVMN | Evommune, Inc. | EVO301 Phase 2a atopic dermatitis late-breaking data presentation at EADV16:30-16:45 CEST, Hall A. Topline was already released in February; this is a conference presentation. | HISTORICAL — Occurrence unverified | Primary source |
| Oct 2, 2026 | $SANA | Sana Biotechnology, Inc. | UP421 clinical-data symposium at EASD 2026Presentation day confirmed; no presentation time inferred. | HISTORICAL — Occurrence unverified | Primary source |
| $TRDA | Entrada Therapeutics | ENTR-601-44 pharmacokinetic / pharmacodynamic translation presentation at WMSScientific presentation; not assumed to be a new patient efficacy readout. Stock Hub | HISTORICAL — Occurrence unverified | Primary source | |
| Sep 27–30, 2026 (conference) | $BIAF | bioAffinity Technologies, Inc. | CyPath Lung posters at NAVREF 2026The individual poster presentation days have not been announced. | HISTORICAL — Occurrence unverified | Primary source |
| Q3 2026 | $QURE | uniQure N.V. | AMT-130 four-year Phase 1/2 analysis in Huntington's diseaseSeptember 30 is an indicative end-of-window marker. No four-year analysis release was found through September 27. | HISTORICAL — Estimate expired; outcome unverified | Primary source |
| Q3 2026 | $CRMD | CorMedix Therapeutics | REZZAYO prophylaxis sNDA submissionCompany-guided submission window; submission not yet confirmed in the sources reviewed. | HISTORICAL — Estimate expired; outcome unverified | Primary source |
| End of September 2026 | $MLTX | MoonLake Immunotherapeutics | Sonelokimab BLA submission in adult and adolescent hidradenitis suppurativaSeptember 30 is an indicative window-end marker. No filing-completed release was found through September 27. | HISTORICAL — Estimate expired; outcome unverified | Primary source 1 · Primary source 2 |
| Sep 30, 2026 | $BMY | Bristol Myers Squibb | CAMZYOS (mavacamten): FDA approved pediatric oHCM expansion for patients weighing at least 30 kg. | HISTORICAL — FDA approved | Primary source |
| September 29 to October 3, 2026 | $CAPR | Capricor Therapeutics, Inc. | Deramiocel HOPE-3 and HOPE-3 OLE presentations at WMS 2026September 29 is conference-start marker, not a verified readout day. HOPE-3 oral presentation is confirmed October 3. Late-breaking HOPE-3 OLE poster day is not specified by this release. Conference in Hiroshima, Japan. | Conference range | Primary source |
The Tracker shows a curated feed of upcoming catalysts and open windows; the Calendar also retains history. The AI Lookup searches the web for current information on the complete ticker universe, including tickers with only historical events. ClinicalTrials.gov data-collection dates are not results-publication dates. Windows and deadlines can change. Educational information only; not financial advice.
Below: clinical and corporate events with a confirmed day, conferences, company windows and recent history, every entry with its primary source, plus the full event calendar, the Catalyst Lookup and the glossary.
Free. No signup. Educational information, not a recommendation.
The free Biotech Catalyst Calendar combines an embedded archive with a sourced selection of regulatory deadlines, clinical readouts, congress presentations and company milestones. Exact dates and estimated windows are labeled separately; completed events remain in history.
The page also includes a glossary covering key FDA, clinical trial, and catalyst terminology, including regulatory designations, trial progress stages, and common clinical metrics. All data is sourced from public information and may contain errors or estimated dates; users are advised to verify with official sources before making any decisions.
Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.
Automatically generated AI snapshot
Enter a ticker to receive a snapshot generated by artificial intelligence using web sources. Responses are not individually checked by a person before they are displayed.
Dates, events and sources may be incomplete, incorrect or out of date. Check the information against official company releases, SEC filings, FDA documents or ClinicalTrials.gov. Estimated dates are not firm deadlines.
For information and education only. Not investment advice or a recommendation to buy or sell securities.
Read the full disclaimerQuick definitions for FDA, clinical-trial, and “catalyst” terms used in the calendar & trackers.
| Term | Meaning |
|---|---|
| PDUFA date | FDA target action date for an NDA/BLA decision (often disclosed via filings/press releases). |
| Priority Review | FDA review goal generally 6 months; the clock depends on the application type. It does not guarantee approval or a decision on a fixed date. |
| Standard Review | FDA review goal generally 10 months; clock start and pathway depend on the application. |
| AdCom | Advisory committee: reviews evidence and may vote; a meeting does not imply approval and its advice is not binding on FDA. |
| NDA / BLA | Applications to approve a drug (NDA) or a biologic (BLA). |
| sNDA / sBLA | Supplemental application (label expansion, new population, new formulation, etc.). |
| Filing acceptance | FDA accepts the application as sufficiently complete to start review (often when PDUFA is set). |
| RTF (Refuse-to-File) | FDA declines to accept an application for review (formal/technical deficiencies). |
| CRL (Complete Response Letter) | FDA does not approve at that time and requests additional info/changes before resubmission. |
| Resubmission (Class 1 / Class 2) | Re-file after CRL; Class 1 = minor changes (often shorter), Class 2 = major (often longer). |
| PDUFA delay/extension | FDA pushes the action date (more time needed for review, inspections, analyses, etc.). |
| Term | Meaning |
|---|---|
| Type A | Urgent/critical meeting (clinical hold, disputes, time-sensitive issues). |
| Type B | Standard “milestone” meeting (End-of-Phase, pre-NDA/BLA, etc.). |
| Type C | Other focused meeting on specific topics; can still be strategically important. |
| EOP (End-of-Phase) | Aligns requirements to move forward (next phase / registrational plan / filing path). |
| SPA | Special Protocol Assessment: FDA agrees in advance on design/endpoint of a key trial (not a guarantee). |
| Term | Meaning | Data released? |
|---|---|---|
| Enrollment Initiation | First sites/patients start enrolling. | NO |
| Enrollment Complete | Enrollment finished (no more new patients). | NO |
| Trial Completed | Final protocol-defined data collection completed. Primary completion concerns primary outcomes; study completion includes secondary outcomes and adverse events. Neither means results have been published. | NO |
| Database Lock | Dataset is finalized for analysis (internal milestone). | NO |
| Interim Data | Results from an interim analysis, which may remain internal. They count as released data only when publicly disclosed. | IF DISCLOSED |
| Topline Data | High-level results release (often via PR/filing). | YES |
| Data Released / Readout | Results publicly disclosed; internal analysis alone does not constitute a public readout. | YES |
| Full Results / Full Dataset | Detailed results published or presented; does not necessarily mean access to the full raw dataset. | YES |
| Conference Presentation | Abstract, poster or oral presentation. A scheduled slot alone does not establish that new results have been released. | IF DISCLOSED |
| Publication | Peer-reviewed paper / full write-up. | YES |
| Term | Meaning |
|---|---|
| OS | Overall Survival. |
| PFS | Progression-Free Survival. |
| ORR | Objective Response Rate (CR + PR). |
| CR / PR | Complete / Partial Response. |
| SD / PD | Stable Disease / Progressive Disease. |
| DOR | Duration of Response. |
| AE / SAE | Adverse event / serious adverse event under regulatory criteria, such as death, life-threatening events or hospitalization. Seriousness differs from severity of intensity; causation is not automatic. |
| PK / PD | Pharmacokinetics / Pharmacodynamics. |
| Biomarker | Biological marker used for selection/response/target engagement. |
| Term | Meaning |
|---|---|
| ODD | Orphan Drug Designation (rare-disease incentives). |
| FTD | Fast Track Designation (more frequent interactions; potential rolling submission). |
| BTD | Breakthrough Therapy Designation: preliminary clinical evidence of potential substantial improvement on clinically significant endpoints over available therapies for a serious condition. It is not approval. |
| RMAT | Designation for eligible regenerative therapies, including certain cell, tissue and gene therapies, with preliminary clinical evidence of potential to address unmet needs in serious conditions. It is not approval. |
| RPDD / PRV | RPDD is a rare pediatric disease designation. A PRV is a separate voucher that may be awarded with a qualifying approval and transferred or used to request priority review of another application. Designation guarantees neither a voucher nor approval. |
| Field | Meaning |
|---|---|
| Stage | Program phase (Preclinical, Phase 1/2/3, NDA/BLA Filing, PDUFA, etc.). |
| Status | Operational status (Ongoing, Trial Completed, Data Released, Clinical Hold, etc.). |
| Next catalyst | Next expected milestone (Topline, Interim, Conference, Submission, Regulatory Decision). |
| Catalyst date | Date or time window (exact / month / quarter / half / year / range). |
Glossary sources: FDA BTD · FDA RMAT · FDA RPDD/PRV · FDA SAE · ClinicalTrials.gov
Stock Hub follow-up, September 27, 2026: 18 missing events added for CGEM, TRDA, SRPT, ORKA and PRAX, checked against sponsor or SEC disclosures. Existing relutrigine and EVERLAST entries were preserved. Scheduled scientific presentations are distinguished from new efficacy readouts; company windows remain estimates. This targeted addition does not re-verify unrelated archive entries.
Sources: FDA documents, SEC filings, sponsor releases and ClinicalTrials.gov. The September 27, 2026 review integrates 49 new or recovered future milestones, updates ACET, ACIU, XENE and CAPR, and separates completed events into history. Other entries retain earlier September 19–26 checks; this update does not re-certify every archive entry. The embedded calendar may include historical events and estimated windows. Registry dates concern data collection, not necessarily public readouts. Stated times include their timezone; EDT is New York daylight time and CEST is daylight time in Italy.
Join the Merlintrader Telegram channel and receive new catalyst updates as they go live.
Join @merlintraderpub_com on TelegramThe dates and events shown in this calendar are collected from publicly available sources and company communications, but may change at any time and may contain errors, inaccuracies, delays or omissions. Some dates are estimated, some timelines may be revised, and certain catalysts may be postponed, cancelled or updated without notice. Always verify with official press releases, SEC filings and primary company sources before making any trading or investment decision.
This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.